[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 432
1. Yoon JH, Park JA, Kim EK, Kang HJ, Shin HY, Ahn HS: Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia. J Korean Med Sci; 2009 Apr;24(2):281-8
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.
  • Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL.
  • Twenty-eight patients diagnosed with relapsed ALL received induction chemotherapy according to the CCG-1884 protocol.
  • In conclusion, a modified dose of idarubicin from 12.5 mg/m(2)/week to 10 mg/m(2)/week resulted in an improved CR rate in the treatment of relapsed ALL, which was due to lower TRM.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Idarubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] Tumori. 1980 Oct 31;66(5):549-64 [6936969.001]
  • [Cites] N Engl J Med. 1981 Oct 8;305(15):846-51 [7024804.001]
  • [Cites] N Engl J Med. 1986 Jul 31;315(5):273-8 [3523250.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):2990-5 [3471321.001]
  • [Cites] Blood. 1987 Jul;70(1):324-6 [3297205.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Cancer Res. 1990 Oct 15;50(20):6525-8 [2208112.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1666-74 [2015395.001]
  • [Cites] Blood. 1992 Jan 15;79(2):313-9 [1730080.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):124-9 [1734217.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1103-11 [1607916.001]
  • [Cites] Blood. 1991 Nov 15;78(10):2780-4 [1824271.001]
  • [Cites] J Clin Oncol. 1995 Feb;13(2):352-8 [7844596.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Med Pediatr Oncol. 1997 Dec;29(6):534-40 [9324340.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8 [16462575.001]
  • [Cites] Curr Opin Hematol. 2006 Jul;13(4):260-5 [16755223.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):581-7 [12209751.001]
  • (PMID = 19399271.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2672129
  • [Keywords] NOTNLM ; Idarubicin / Precursor Cell Lymphoblastic Leukemia-Lymphoma / Recurrence / Remission Induction
  •  go-up   go-down


2. Messinger Y, Gaynon P, Raetz E, Hutchinson R, Dubois S, Glade-Bender J, Sposto R, van der Giessen J, Eckroth E, Bostrom BC: Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatr Blood Cancer; 2010 Aug;55(2):254-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia (TACL) consortium.
  • BACKGROUND: Outcomes remain poor for children after relapse of acute lymphoblastic leukemia (ALL), especially after early marrow relapse.
  • Bortezomib is a proteasome inhibitor with in vitro synergy with corticosteroids and clinical activity in human lymphoid malignancies.
  • PROCEDURE: This is a Phase I study of escalating doses bortezomib administered days 1, 4, 8, and 11, added to 4-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin (VXLD) in children with relapsed ALL.
  • Six of nine evaluable patients (67%) achieved a complete response (CR), and one had a bone marrow CR with persistent central nervous system leukemia.
  • CONCLUSIONS: The combination of bortezomib (1.3 mg/m(2)) with VXLD is active with acceptable toxicity in pretreated pediatric patients with relapsed ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrazines / administration & dosage


3. Su WJ, Chen HL, Lai HS, Ni YH, Chang MH: Pancreaticobiliary anomalies is the leading cause of childhood recurrent pancreatitis. J Formos Med Assoc; 2007 Feb;106(2):119-25
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreaticobiliary anomalies is the leading cause of childhood recurrent pancreatitis.
  • BACKGROUND/PURPOSE: To explore the etiology, age and gender distribution, complications, and prognosis of recurrent pediatric pancreatitis.
  • Only 25 diagnosed with recurrent pancreatitis, based on two or more episodes of pancreatitis, elevated serum amylase and/or lipase levels > or = 3 times the upper limit of normal, radiographic evidence, and clinical symptoms, were enrolled.
  • The recurrence rate of pediatric pancreatitis was 27.2%.
  • Recurrent pancreatitis was associated with pancreaticobiliary structural anomalies (n = 7), biliary stones or sludge (n = 4), hyperlipidemia (n = 3), pseudopapillary tumor of the pancreas (n = 2), trauma (n = 2), hypoxic encephalopathy with recurrent bacteremia and sepsis (n = 1), and idiopathic (n = 6).
  • No patient died of recurrent pancreatitis.
  • Long-term morbidity after recurrent pancreatitis presented as gout, diabetes mellitus, non-alcoholic steatohepatitis, and chronic pancreatitis.
  • CONCLUSION: For children who suffer from recurrent pancreatitis, pancreaticobiliary structural anomalies should be considered first.

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17339155.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


Advertisement
4. von Stackelberg A, Hartmann R, Bührer C, Fengler R, Janka-Schaub G, Reiter A, Mann G, Schmiegelow K, Ratei R, Klingebiel T, Ritter J, Henze G, ALL-REZ BFM Study Group: High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia. Blood; 2008 Mar 1;111(5):2573-80
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose compared with intermediate-dose methotrexate in children with a first relapse of acute lymphoblastic leukemia.
  • High-dose methotrexate (MTX) has been extensively used for treatment of acute lymphoblastic leukemia (ALL).
  • To determine the optimal dose of MTX in childhood relapsed ALL, the ALL Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group performed this prospective randomized study.
  • A total of 269 children with a first early/late isolated (n = 156) or combined (n = 68) bone marrow or any isolated extramedullary relapse (n = 45) of precursor B-cell (PBC) ALL (excluding very early marrow relapse within 18 months after initial diagnosis) were registered at the ALL-REZ BFM90 trial and randomized to receive methotrexate infusions at either 1 g/m(2) over 36 hours (intermediate dose, ID) or 5 g/m(2) over 24 hours (high dose, HD) during 6 (or 4) intensive polychemotherapy courses.
  • In conclusion, methotrexate infusions at 5 g/m(2) per 24 hours, compared with 1 g/m(2) per 36 hours, are not associated with increased disease control in relapsed childhood PBC acute lymphoblastic leukemia.
  • [MeSH-major] Methotrexate / administration & dosage. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2008 Aug 1;112(3):910 [18650464.001]
  • (PMID = 18089849.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, Sandlund JT, Howard SC: Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer; 2010 Sep 15;116(18):4376-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients.
  • BACKGROUND: Pediatric Hodgkin lymphoma (HL) is a highly curable disease; however, prognostic factors for the survival of patients who develop recurrent disease have not been clearly defined.
  • METHODS: This was a retrospective analysis of 50 pediatric patients with HL who relapsed or progressed between 1990 and 2006 and who were retrieved with intense cytoreductive treatment regimens followed by autologous stem cell transplantation and radiation therapy.
  • Fifteen patients developed progressive disease during therapy, 14 patients relapsed early, and 21 patients relapsed late.
  • CONCLUSIONS: The current results indicated that pediatric patients with relapsed HL who have an inadequate response after initial primary salvage chemotherapy have a very poor prognosis and should be considered for novel therapies directed at biologic or immunologic targets.

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Cancer Society.
  • [Cites] J Clin Oncol. 1993 Apr;11(4):704-11 [8478664.001]
  • [Cites] Blood. 1993 Mar 1;81(5):1137-45 [8443375.001]
  • [Cites] Radiology. 1997 Jun;203(3):795-800 [9169707.001]
  • [Cites] Radiology. 1998 Feb;206(2):475-81 [9457202.001]
  • [Cites] Ann Oncol. 1998 Mar;9(3):289-95 [9602263.001]
  • [Cites] Bone Marrow Transplant. 1998 Aug;22(3):265-71 [9720740.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1506-14 [9819449.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3101-9 [10506605.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4532-40 [15542804.001]
  • [Cites] J Clin Oncol. 2004 Nov 15;22(22):4541-50 [15542805.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Nov;26(11):740-5 [15543009.001]
  • [Cites] Br J Haematol. 2005 Aug;130(3):363-72 [16042685.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):6181-9 [16135485.001]
  • [Cites] Blood. 2006 Jan 1;107(1):52-9 [16150944.001]
  • [Cites] Haematologica. 2006 Apr;91(4):475-81 [16585014.001]
  • [Cites] Haematologica. 2006 Apr;91(4):482-9 [16585015.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):189-95 [16601441.001]
  • [Cites] Ann Hematol. 2006 Nov;85(11):759-67 [16871391.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1065-72 [17084370.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2007 Jan;34(1):60-7 [17021808.001]
  • [Cites] Radiology. 2007 Jul;244(1):257-62 [17581905.001]
  • [Cites] Semin Radiat Oncol. 2007 Jul;17(3):230-42 [17591570.001]
  • [Cites] Blood. 2000 Aug 15;96(4):1280-6 [10942369.001]
  • [Cites] Blood. 2001 Jan 15;97(2):404-9 [11154216.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):221-30 [11773173.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):630-7 [11821442.001]
  • [Cites] Ann Oncol. 2002;13 Suppl 1:112-6 [12078891.001]
  • [Cites] Lancet. 2002 Jun 15;359(9323):2065-71 [12086759.001]
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3081-7 [12118021.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10):2026-33 [12743158.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Br J Haematol. 1992 Jun;81(2):197-202 [1643017.001]
  • [Cites] J Clin Oncol. 1993 Jan;11(1):100-8 [8418221.001]
  • [Cites] J Clin Oncol. 1993 Dec;11(12):2351-61 [8246024.001]
  • (PMID = 20564743.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-78224; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R37 CA036401-24; United States / NCI NIH HHS / CA / CA-60419; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / CA078224-10; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; None / None / / R01 CA051001-15; United States / NCI NIH HHS / CA / CA-36401; United States / NIGMS NIH HHS / GM / GM061393-100007; United States / NCI NIH HHS / CA / R01 CA060419; United States / NCI NIH HHS / CA / CA-51001; United States / NCI NIH HHS / CA / CA036401-24; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / R01 CA051001-15; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA078224-10; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / R01 CA051001; United States / NCI NIH HHS / CA / R01 CA036401; United States / NIGMS NIH HHS / GM / U01 GM061393-100007; United States / NIGMS NIH HHS / GM / GM-61393; United States / NCI NIH HHS / CA / U01 CA060419
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS189726; NLM/ PMC2936658
  •  go-up   go-down


6. Styczynski J, Gil L, Derwich K, Wachowiak J, Balwierz W, Badowska W, Krawczuk-Rybak M, Matysiak M, Wieczorek M, Balcerska A, Sonta-Jakimczyk D, Stefaniak J, Kowalczyk J, Urasinski T, Sobol G, Komarnicki M, Wysocki M: Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study. Anticancer Res; 2009 May;29(5):1643-50
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of clofarabine activity in childhood and adult acute leukemia: individual tumor response study.
  • The aim of the study was the analysis of ex vivo activity of clofarabine and 14 other anticancer drugs in pediatric and adult acute lymphoblastic (ALL) and myeloid (AML) leukemia.
  • PATIENTS AND METHODS: The ex vivo drug resistance profile was analyzed in 282 patients, including 201 children with ALL de novo, 24 children with relapsed ALL, 25 children with AML de novo and 32 adults with AML.
  • Its activity in acute myeloid leukemia was independent of patient age.
  • No significant differences in drug resistance to clofarabine between pediatric age-based subgroups of ALL were detected, while it was observed for most of other drugs.
  • An activity of clofarabine in relapsed pediatric ALL patients was as good as in newly-diagnosed ones.
  • CONCLUSION: In comparison to childhood acute lymphoblastic leukemia, lack of differences in ex vivo activity gives rationale for use of clofarabine in refractory and relapsed pediatric and adult patients with acute myeloid leukemia.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Humans. Infant. Middle Aged. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443380.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


7. Hoffer FA, Daw NC, Xiong X, Anghelescu D, Krasin M, Yan X, Davidoff AM, Furman WL, Rodriguez-Galindo C, Spunt SL: A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer; 2009 Mar 15;115(6):1328-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors.
  • BACKGROUND: This prospective study was designed to be the first to evaluate the toxicity of radiofrequency ablation (RFA) in patients with recurrent pediatric solid tumors.
  • METHODS: From 2003 through 2008, a phase 1/pilot study of RFA for recurrent pediatric solid tumors was conducted.
  • CONCLUSIONS: The toxicity from RFA of recurrent pediatric solid tumors was real but limited, and RFA may offer a local tumor control alternative in carefully selected cases.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [Cites] Pediatr Radiol. 2005 Sep;35(9):923-8 [15928925.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):3021-7 [9738571.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Nov;132(11):1251-6 [17116823.001]
  • [Cites] Pediatr Radiol. 2007 Mar;37(3):297-300 [17216171.001]
  • [Cites] Radiology. 2007 Apr;243(1):268-75 [17392258.001]
  • [Cites] Radiology. 2007 Jun;243(3):877-84 [17517940.001]
  • [Cites] J Pediatr Surg. 2007 Aug;42(8):E5-8 [17706486.001]
  • [Cites] Am Surg. 2008 Feb;74(2):129-32 [18306862.001]
  • [Cites] Radiology. 2008 Jun;247(3):871-9 [18372457.001]
  • [Cites] Paediatr Anaesth. 2008 Nov;18(11):1131-3 [18950355.001]
  • [Cites] J Pediatr Hematol Oncol. 2005 Jul;27(7):377-9 [16012327.001]
  • [Cites] Cancer. 2001 Mar 15;91(6):1170-6 [11267963.001]
  • [Cites] Pediatr Radiol. 2002 Aug;32(8):615-8 [12200642.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] J Vasc Interv Radiol. 2003 May;14(5):629-34 [12761317.001]
  • [Cites] Med Pediatr Oncol. 2003 Nov;41(5):476-7 [14515395.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):300-6 [14722039.001]
  • [Cites] J Pediatr Surg. 2004 Mar;39(3):282-6; discussion 282-6 [15017538.001]
  • [Cites] Am J Gastroenterol. 1997 Jan;92(1):156-8 [8995959.001]
  • [Cites] AORN J. 2006 Mar;83(3):658-64; quiz 665-7 [16579122.001]
  • (PMID = 19180637.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA021765-31
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS167616; NLM/ PMC2814781
  •  go-up   go-down


8. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wieczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmicz M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, Maciejka-Kapuscinska L: Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. J Cancer Res Clin Oncol; 2007 Nov;133(11):875-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
  • PURPOSE: Cellular resistance in childhood acute leukemias might be related to profile and function of multidrug resistance proteins and apoptosis regulating proteins.
  • (2) correlation with ex vivo drug resistance, and (3) analysis of their prognostic impact on clinical outcome in childhood acute lymphoblastic (ALL) and acute myeloid (AML) leukemia.
  • METHODS: Total number of 787 children diagnosed for initial ALL (n = 527), relapsed ALL (n = 104), initial AML (n = 133) and relapsed AML (n = 23) were included into the study.
  • RESULTS: Both initial AML and relapsed ALL samples showed higher drug resistance than initial ALL samples.
  • No significant differences were found in drug resistance between initial and relapsed AML samples.
  • CONCLUSIONS: The phenomenon of cellular drug resistance in childhood acute leukemias is multifactorial and plays an important role in response to therapy.
  • Expression of MRP1, PGP and LRP proteins, as well as their co-expression play possible role in childhood relapsed ALL.
  • [MeSH-major] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Cancer Res Clin Oncol. 2007 Nov;133(11):895. Wachowiak, Jacek [added]; Konatkowska, Benigna [added]; Gil, Lidia [added]; Balcerska, Anna [added]; Maciejka-Kapuscinska, Lucyna [added]
  • [Cites] Med Pediatr Oncol. 2002 Jun;38(6):379-86 [11984797.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3B):2253-8 [16158972.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3120-6 [11595704.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Jan-Feb;22(1):45-9 [10695821.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3352-60 [12384437.001]
  • [Cites] Leukemia. 1994 Jul;8(7):1224-9 [8035616.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2125-9 [16281077.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):85-95 [12691146.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2092-8 [9490695.001]
  • [Cites] Br J Haematol. 1998 Aug;102(3):647-55 [9722289.001]
  • [Cites] Leukemia. 1995 Nov;9(11):1864-9 [7475276.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4493-8 [12816874.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):264-79 [15491285.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):963-4 [14990658.001]
  • [Cites] Pediatr Int. 1999 Dec;41(6):641-7 [10618884.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Leukemia. 1999 Dec;13(12):2023-30 [10602424.001]
  • [Cites] Pediatr Blood Cancer. 2004 Feb;42(2):195-9 [14752887.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2879-86 [11023525.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 1999 Nov;38(11):760-3 [11798719.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] Klin Padiatr. 2005 Nov-Dec;217(6):310-20 [16307416.001]
  • [Cites] Leuk Lymphoma. 2002 Sep;43(9):1843-8 [12685842.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1083-6 [12631611.001]
  • [Cites] Br J Haematol. 1999 Jun;105(4):876-82 [10554796.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leuk Lymphoma. 1994 Apr;13(3-4):187-201 [8049644.001]
  • [Cites] Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110 [10739113.001]
  • [Cites] Klin Padiatr. 1987 May-Jun;199(3):151-60 [3306129.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2117-24 [16107894.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3262-8 [12947061.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):998-1006 [10749961.001]
  • [Cites] Lancet. 1998 Nov 28;352(9142):1731-8 [9848348.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] Curr Opin Oncol. 1995 Jan;7(1):36-44 [7696362.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2387-94 [12816873.001]
  • [Cites] Expert Rev Mol Diagn. 2004 Sep;4(5):705-13 [15347263.001]
  • [Cites] J Endocrinol. 2003 Jul;178(1):19-27 [12844332.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 2002 Mar;41(3):183-5 [11940320.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8661-8 [16361551.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):599-604 [10404077.001]
  • [Cites] Sao Paulo Med J. 2004 Jul 1;122(4):166-71 [15543372.001]
  • [Cites] Leuk Lymphoma. 2002 Apr;43(4):875-9 [12153178.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Ai Zheng. 2005 Aug;24(8):1015-7 [16086885.001]
  • [Cites] Exp Hematol. 1998 Nov;26(12):1111-7 [9808049.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2063-71 [16107896.001]
  • [Cites] Br J Haematol. 1999 Feb;104(2):321-7 [10050715.001]
  • [Cites] Exp Hematol. 2002 Nov;30(11):1302-8 [12423683.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 17671794.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein
  •  go-up   go-down


9. Gidwani P, Ramesh KH, Liu Y, Kolb EA: The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy; 2008;54(2):120-4
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.
  • BACKGROUND: Despite significant advances in treatment and survival rates in pediatric acute leukemias, relapse remains a common reason for treatment failure.
  • Clofarabine, a purine nucleoside analog, has recently been approved for use in relapsed and refractory pediatric acute lymphoblastic leukemia.
  • Clofarabine and cytarabine together may be synergistic and have been used safely in adult leukemia patients.
  • CASE REPORT: We describe the administration of this combination to a 9-year-old boy with multiple relapsed T-cell acute lymphoblastic leukemia who failed to achieve remission after the third attempt.
  • CONCLUSION: This case is the first report of successful remission induction in a multiple relapsed pediatric leukemia patient using the clofarabine and cytarabine combination.
  • Although it is a single case, it highlights the need for further studies to assess safety and efficacy of this combination in pediatric patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303261.001).
  • [ISSN] 1421-9794
  • [Journal-full-title] Chemotherapy
  • [ISO-abbreviation] Chemotherapy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 04079A1RDZ / Cytarabine; 762RDY0Y2H / clofarabine
  •  go-up   go-down


10. Wu S, Gessner R, Taube T, von Stackelberg A, Henze G, Seeger K: Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol; 2005 May 1;23(13):3038-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of interleukin-10 splicing variants is a positive prognostic feature in relapsed childhood acute lymphoblastic leukemia.
  • This study aimed to determine the expression of a splicing-derived variant of interleukin (IL) -10 in leukemic cells and its clinical relevance in children with acute lymphoblastic leukemia (ALL) at first relapse.
  • CONCLUSION: These results indicate that splicing-derived IL-10 isoforms may modulate IL-10-mediated biologic effects and therapeutic efficacy in lymphatic disease, and expression of IL-10delta3 is a positive prognostic feature in relapsed childhood ALL.
  • [MeSH-major] Gene Expression Profiling. Genetic Variation. Interleukin-10 / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860861.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 130068-27-8 / Interleukin-10
  •  go-up   go-down


11. Kawamata N, Ogawa S, Seeger K, Kirschner-Schwabe R, Huynh T, Chen J, Megrabian N, Harbott J, Zimmermann M, Henze G, Schrappe M, Bartram CR, Koeffler HP: Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia. Int J Oncol; 2009 Jun;34(6):1603-12
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular allelokaryotyping of relapsed pediatric acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia (ALL) cells at relapse are frequently more resistant to treatment than primary clones and this may be caused by further genetic changes in the ALL cells at relapse.
  • [MeSH-major] Chromosome Aberrations. Gene Expression Regulation, Leukemic. Neoplasm Recurrence, Local / genetics. Polymorphism, Single Nucleotide / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19424578.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; EC 3.1.3.48 / PTPRD protein, human; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 2; EC 3.6.5.2 / ADP-Ribosylation Factor 1
  •  go-up   go-down


12. Davidsson J, Paulsson K, Lindgren D, Lilljebjörn H, Chaplin T, Forestier E, Andersen MK, Nordgren A, Rosenquist R, Fioretos T, Young BD, Johansson B: Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations. Leukemia; 2010 May;24(5):924-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relapsed childhood high hyperdiploid acute lymphoblastic leukemia: presence of preleukemic ancestral clones and the secondary nature of microdeletions and RTK-RAS mutations.
  • Although childhood high hyperdiploid acute lymphoblastic leukemia is associated with a favorable outcome, 20% of patients still relapse.
  • No single aberration was linked to relapse, but four deletions, involving IKZF1, PAX5, CDKN2A/B or AK3, were recurrent.
  • [MeSH-major] Chromosome Deletion. Diploidy. Genes, ras / genetics. Mutation / genetics. Neoplasm Recurrence, Local / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Receptor Protein-Tyrosine Kinases / genetics


13. Bader P, Kreyenberg H, Henze GH, Eckert C, Reising M, Willasch A, Barth A, Borkhardt A, Peters C, Handgretinger R, Sykora KW, Holter W, Kabisch H, Klingebiel T, von Stackelberg A, ALL-REZ BFM Study Group: Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol; 2009 Jan 20;27(3):377-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
  • PURPOSE: Minimal residual disease (MRD) before allogeneic stem-cell transplantation was shown to predict outcome in children with relapsed acute lymphoblastic leukemia (ALL) in retrospective analysis.
  • To verify this, the Acute Lymphoblastic Leukemia Relapse Berlin-Frankfurt-Münster (ALL-REZ BFM) Study Group conducted a prospective trial.
  • PATIENTS AND METHODS: Between March 1999 and July 2005, 91 children with relapsed ALL treated according to the ALL-REZ BFM 96 or 2002 protocols and receiving stem-cell transplantation in >or= second remission were enrolled.
  • [MeSH-major] Neoplasm, Residual / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Stem Cell Transplantation


14. Matsuzaki A, Nagatoshi Y, Inada H, Nakayama H, Yanai F, Ayukawa H, Kawakami K, Moritake H, Suminoe A, Okamura J: Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group. Pediatr Blood Cancer; 2005 Aug;45(2):111-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
  • BACKGROUND: The treatment results of childhood acute lymphoblastic leukemia (ALL) with a first relapse were retrospectively analyzed to determine prognostic factors.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation


15. Sandri A, Massimino M, Mastrodicasa L, Sardi N, Bertin D, Basso ME, Todisco L, Paglino A, Perilongo G, Genitori L, Valentini L, Ricardi U, Gandola L, Giangaspero F, Madon E: Treatment with oral etoposide for childhood recurrent ependymomas. J Pediatr Hematol Oncol; 2005 Sep;27(9):486-90
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with oral etoposide for childhood recurrent ependymomas.
  • In this study the authors retrospectively evaluated the feasibility and effectiveness of prolonged oral etoposide therapy in children with recurrent ependymoma.
  • Twelve ependymoma patients with documented recurrent or persistent disease were treated between May 1998 and October 2003.
  • These results emphasize that oral etoposide is an attractive option for childhood recurrent ependymomas in terms of administration, tolerability, and neuroradiologic response.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16189442.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


16. Reismüller B, Attarbaschi A, Peters C, Dworzak MN, Pötschger U, Urban C, Fink FM, Meister B, Schmitt K, Dieckmann K, Henze G, Haas OA, Gadner H, Mann G, Austrian Berlin-Frankfurt-Münster (BFM) Study Group: Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group. Br J Haematol; 2009 Feb;144(4):559-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria--a population-based report of the Austrian Berlin-Frankfurt-Münster (BFM) Study Group.
  • Relapsed acute lymphoblastic leukaemia (ALL) is the most common cause for a fatal outcome in paediatric oncology.
  • Although initial ALL cure rates have improved up to 80%, the prognosis of recurrent ALL remains dismal with event-free-survival (EFS) rates about 35%.
  • In order to analyse a population-based cohort with uniform treatment of initial disease, we examined the outcome of children suffering from relapsed ALL in Austria for the past 20 years and the validity of the currently used prognostic factors (e.g. time to and site of relapse, immunophenotype).
  • Of these, 203 (23%) suffered from recurrent disease.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077160.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  • [Investigator] Ausserer B; Busch U; Müller G; Kurz R; Urban Ch; Berger H; Fink FM; Meister B; Kaulfersch W; Messner H; Mutz I; Stöllinger O; Tulzer W; Schmidt K; Ebetsberger T; Grienberger H; Jones N; Jones R; Rücker J; Haas H; Ploier R; Gadner H; Grümayer-Panzer ER; Krepler P; Mann G; Pichler E; Jürgenssen O; Slavc I; Höcker P; Knapp W; Pickl WF; Haas OA; Lion T; Kärcher KH; Hawlicek R; Pötter R; Dieckmann K
  •  go-up   go-down


17. Grill J, Perek D, Sanchez de Toledo-Codina J, Madero L, Estlin E, Cañete A, Icher C, Breazna A, Geoerger B, Cisar L, Hargrave D: Phase II single-arm study of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma. J Clin Oncol; 2009 May 20;27(15_suppl):10018

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II single-arm study of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma.
  • : 10018 Background: Irinotecan and temozolomide have demonstrated moderate single agent activity in childhood medulloblastoma (MB).
  • Using the recommended dose established from a prior pediatric phase I study, the combination of irinotecan and temozolomide was investigated in relapsed MB.
  • METHODS: Patients aged 6 months to 18 years with radiological measurable relapsed/refractory MB were treated with temozolomide 100-125 mg/m2/day on days 1-5 orally and irinotecan 10 mg/m2/day on days 1-5 and days 8-12 intravenously.
  • The number of relapsed patients with M3:M2:M1:M0 (Chang M stage) were 10:15:2:6, and 17 had more than 1 prior therapy.
  • CONCLUSIONS: This multi-centre international study is the largest phase II trial of the irinotecan and temozolomide combination in pediatric central nervous system tumors.
  • The activity of the combination in heavily pre-treated recurrent MB patients is promising.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962503.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Kaszper E, Hanzély Z, Szende B, Dabasi G, Garami M, Schuler D, Hauser P: [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas]. Magy Onkol; 2008 Dec;52(4):351-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Examination of somatostatin receptor expression in recurrent childhood medulloblastomas].
  • Medulloblastoma is the most common malignant pediatric central nervous system tumor.
  • The primary medulloblastoma expresses somatostatin receptor-2 (SSTR-2), but so far we had no experience about the receptor status in recurrent tumors.
  • The presence of SSTR-2 may have an important role in the early detection and treatment of recurrent medulloblastomas.
  • Our aim was to examine the state of SSTR-2 expression in recurrent childhood medulloblastomas.
  • We examined SSTR-2 expression by immunohistochemistry in primary and recurrent medulloblastoma samples of ten children treated with recurrent medulloblastoma at Semmelweis University, Departments of Pediatrics, between 1998 and 2004.
  • All primary and recurrent tumors have been operated at the National Institute of Neurosurgery.
  • We examined the intensity and the percentage of SSTR-2-positive tumor cells in the primary and recurrent tumor samples.
  • All primary tumors were receptor-positive and SSTR-2 was also expressed in all recurrent medulloblastomas.
  • As a conclusion, SSTR-2-positive recurrent tumors can be detected early by Octreoscan imaging, and the presence of SSTR-2 establishes the opportunity of applying somatostatin analogues (octreotide) in the treatment of recurrent childhood medulloblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19068462.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Indium Radioisotopes; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 51110-01-1 / Somatostatin; G083B71P98 / pentetreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


19. Chan KL: Laparoscopic repair of recurrent childhood inguinal hernias after open herniotomy. Hernia; 2007 Feb;11(1):37-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic repair of recurrent childhood inguinal hernias after open herniotomy.
  • BACKGROUND: Open repair of recurrent paediatric inguinal hernias (IH) is difficult and there is definite risk of damaging the vas deferens and testicular vessels during dissection of the previous open herniotomy field.
  • METHOD: Records of patients with recurrent IH that had LR after open repair were reviewed and evaluated retrospectively.
  • RESULTS: From September 2002 to October 2005, four boys and one girl (mean age 58.8 months) were treated in our institution for recurrent IH after open repair.
  • CONCLUSION: Laparoscopic repair is the preferred operation for recurrent childhood IH after open repair.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Endosc. 2004 Jun;18(6):957-60 [15095082.001]
  • [Cites] J Pediatr Surg. 2002 Mar;37(3):395-7 [11877655.001]
  • [Cites] Surg Endosc. 2005 Jul;19(7):927-32 [15920685.001]
  • [Cites] J Am Coll Surg. 2003 Jun;196(6):987-9 [12788439.001]
  • [Cites] Br J Surg. 1985 Jun;72(6):485-7 [4016518.001]
  • [Cites] J Pediatr Surg. 2005 Jun;40(6):1009-14 [15991187.001]
  • [Cites] Acta Chir Belg. 1996 Feb;96(1):28-30 [8629384.001]
  • [Cites] J Pediatr Surg. 1991 Mar;26(3):283-7 [2030473.001]
  • [Cites] East Afr Med J. 1990 May;67(5):359-64 [2390959.001]
  • [Cites] J Pediatr Surg. 2002 May;37(5):745-51 [11987092.001]
  • (PMID = 17006622.001).
  • [ISSN] 1265-4906
  • [Journal-full-title] Hernia : the journal of hernias and abdominal wall surgery
  • [ISO-abbreviation] Hernia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. De Sio L, Milano GM, Castellano A, Jenkner A, Fidani P, Dominici C, Donfrancesco A: Temozolomide in resistant or relapsed pediatric solid tumors. Pediatr Blood Cancer; 2006 Jul;47(1):30-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temozolomide in resistant or relapsed pediatric solid tumors.
  • PURPOSE: We report the off-label study aimed at investigating the use of temozolomide (TMZ) as single agent in relapsed or resistant pediatric solid tumors.
  • PATIENTS AND METHODS: Fifty two patients, median age 127.6 months, with resistant or relapsed solid tumors were enrolled.
  • CONCLUSION: Oral TMZ was well tolerated in children with resistant or relapsed solid tumors and showed activity in NB and CNS tumours refractory to standard chemotherapy.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • [ErratumIn] Pediatr Blood Cancer. 2006 Oct 15;47(5):647-8
  • (PMID = 16047361.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  •  go-up   go-down


21. Connelly M, Rapoff MA, Thompson N, Connelly W: Headstrong: a pilot study of a CD-ROM intervention for recurrent pediatric headache. J Pediatr Psychol; 2006 Aug;31(7):737-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Headstrong: a pilot study of a CD-ROM intervention for recurrent pediatric headache.
  • OBJECTIVES: To empirically evaluate a minimal therapist contact CD-ROM pain management program for recurrent pediatric headache developed as part of this study.
  • METHODS: Participants were 37 children aged 7-12 attending a pediatric neurology clinic for evaluation of recurrent headache.
  • Results provide initial support for the utility of adding an adjunctive CD-ROM psychological intervention to standard medical care for recurrent pediatric headache and potentially other chronic pain conditions in children.

  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16861397.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Fullerton HJ, Wu YW, Sidney S, Johnston SC: Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging. Pediatrics; 2007 Mar;119(3):495-501
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of recurrent childhood arterial ischemic stroke in a population-based cohort: the importance of cerebrovascular imaging.
  • OBJECTIVE: Few data exist regarding rates and predictors of recurrence after childhood arterial ischemic stroke.
  • We used Kaplan-Meier survival-analysis techniques to determine rates and predictors of recurrent stroke.
  • RESULTS: Among 181 incident childhood stroke cases (84 perinatal; 97 later childhood), there were 16 recurrent strokes (1 after a perinatal stroke) at a median of 2.7 months.
  • The 5-year cumulative recurrence rates were 1.2% after perinatal stroke and 19% after later childhood stroke.
  • Of the 97 children with later childhood strokes, 52 received cerebrovascular imaging, predominantly magnetic resonance angiography (n = 36) and conventional angiography (n = 26).
  • CONCLUSIONS: Strokes recur in one fifth of cases of later childhood arterial ischemic stroke but are rare after perinatal stroke.
  • Among the later childhood cases, cerebrovascular imaging identifies those at highest risk for recurrence.

  • Genetic Alliance. consumer health - Ischemic stroke.
  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332202.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K12 NS01692
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibrinolytic Agents
  •  go-up   go-down


23. Ng MH, Lau KM, Hawkins BR, Chik KW, Chan NP, Wong WS, Tsang KS, Shing MM, Li CK: HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003). Ann Hematol; 2006 Aug;85(8):535-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-B67 may be a male-specific HLA marker of susceptibility to relapsed childhood ALL in Hong Kong Chinese and HLA-A33 or HLA-B17 signifies a higher presentation leukocytosis: A retrospective analysis on 53 transplant candidates (1989-2003).
  • We performed a retrospective analysis on the human leukocyte antigen (HLA) data of 53 consecutive Chinese patients with high-risk childhood acute lymphoblastic leukemia (ALL) diagnosed from 1989 to 2003.
  • Taken together, our findings support the involvement of HLA in Chinese high-risk childhood ALL.
  • [MeSH-major] Biomarkers, Tumor / blood. Disease Susceptibility / blood. HLA-A Antigens / blood. HLA-B Antigens / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16710717.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA-A Antigens; 0 / HLA-A*33 antigen; 0 / HLA-B Antigens; 0 / HLA-B17 antigen; 0 / HLA-B67 antigen
  •  go-up   go-down


24. Wehrli LA, Braun J, Buetti LN, Hagleitner N, Hengartner H, Kühne T, Lüer S, Ozsahin H, Popovic MB, Niggli FK, Betts DR, Bourquin JP: Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia. Cancer Genet Cytogenet; 2009 Feb;189(1):29-36
Genetic Alliance. consumer health - Acute Non Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-classical karyotypic features in relapsed childhood B-cell precursor acute lymphoblastic leukemia.
  • Karyotype analysis of acute lymphoblastic leukemia (ALL) at diagnosis has provided valuable prognostic markers for treatment stratification.
  • However, reports of cytogenetic studies of relapsed ALL samples are limited.
  • We compared the karyotypes from 436 nonselected B-cell precursor ALL patients at initial diagnosis and of 76 patients at first relapse.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. Infant. Karyotyping. Male. Recurrence. Translocation, Genetic. Treatment Outcome


25. Berrak SG, Pearson M, Berberoğlu S, Ilhan IE, Jaffe N: High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity. Pediatr Blood Cancer; 2005 Mar;44(3):215-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose ifosfamide in relapsed pediatric osteosarcoma: therapeutic effects and renal toxicity.
  • BACKGROUND: Sixteen pediatric osteosarcoma patients, previously treated with conventional chemotherapy (including ifosfamide (IFX), 9 g/m(2)) were retreated with high-dose ifosfamide (HD-IFX, 14 g/m(2) per course), following relapse or development of a new bone tumor.


26. Jude V, Chan KW: Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia. Curr Hematol Malig Rep; 2010 Jul;5(3):129-34
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.
  • Hematopoietic stem cell transplantation has been an important treatment modality in the management of high-risk or relapsed childhood acute lymphoblastic leukemia.
  • Leukemia recurrence remains a major cause of treatment failure.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy


27. Kaspers GJ, Wijnands JJ, Hartmann R, Huismans L, Loonen AH, Stackelberg A, Henze G, Pieters R, Hählen K, Van Wering ER, Veerman AJ: Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia. Eur J Cancer; 2005 Jun;41(9):1300-3
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.
  • At relapse, T-cell acute lymphoblastic leukaemia (ALL) has a worse patient outcome than B-cell precursor (BCP-) ALL.
  • We investigated 237 paediatric relapsed ALL cases, including 151 samples taken at first relapse, of which 30 were T-cell ALL.
  • Similar results were found for first relapsed ALL samples and for the total group: T-cell ALL samples were more resistant to 4-HOO-ifosfamide (1.4-fold, P = 0.019) and cisplatin (3.7-fold, P = 0.005).
  • These results do not explain the relatively poor prognosis of T-cell ALL at relapse, but do suggest that the more intensive use of thiopurines in relapsed T-cell ALL may be beneficial.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Burkitt Lymphoma / drug therapy. Drug Resistance, Neoplasm / immunology. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15869873.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


28. Nara M, Toyoki Y, Hakamada K, Narumi S, Ishido K, Sugai M, Munakata H, Ito E, Sasaki M: Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma. Transplant Proc; 2008 Oct;40(8):2828-9
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Living donor liver transplantation for a child with recurrent pediatric adult-type hepatocellular carcinoma.
  • INTRODUCTION: Pediatric hepatocellular carcinoma (HCC) is an uncommon disease with a poor prognosis.
  • There are few reports about liver transplantation for pediatric adult-type HCC.
  • We experienced a case of living donor liver transplantation (LDLT) for a child with recurrent pediatric adult-type HCC.
  • However, his alpha-fetoprotein level increased and a computed tomography (CT) scan showed recurrent tumor in his remnant liver in October 2006.
  • CONCLUSION: Liver transplantation in conjunction with chemotherapy may have an increasing role in the management of pediatric HCC.


29. Gandhi V, Plunkett W: Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol; 2006 Nov;18(6):584-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: Both clofarabine and nelarabine recently received an accelerated approval by the US Food and Drug Administration for use in refractory or relapsed pediatric acute lymphoblastic leukemia and in refractory-relapsed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
  • Several phase I and II clinical explorations have suggested the utility of clofarabine in acute leukemias and nelarabine in T-cell diseases.
  • SUMMARY: Clofarabine is the first deoxyadenosine analog that shows promise in adult and pediatric acute leukemias without untoward toxicity.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16988579.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA57629; United States / NCI NIH HHS / CA / CA81534
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Number-of-references] 68
  •  go-up   go-down


30. Haltrich I, Csóka M, Kovács G, Fekete G: [Cytogenetic and FISH findings are complementary in childhood ALL]. Magy Onkol; 2008 Sep;52(3):283-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic and FISH findings are complementary in childhood ALL].
  • Primary genetic abnormalities of leukemia cells have important prognostic significance in childhood acute leukemia.
  • In the last two years 30 newly diagnosed or recurrent childhood ALL bone marrow samples were analyzed for chromosomal abnormalities with conventional G-banding and interphase-fluorescence in situ hybridization (I-FISH) using probes to detect BCR/ABL fusions, cryptic TEL/AML1 and MLL rearrangements and p16(9p21) tumor suppressor gene deletions.
  • [MeSH-major] Chromosome Aberrations. Chromosomes, Human, Pair 21. Gene Rearrangement. In Situ Hybridization, Fluorescence. Oncogene Proteins, Fusion / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Chromosome Banding. Core Binding Factor Alpha 2 Subunit / genetics. Female. Fusion Proteins, bcr-abl / genetics. Gene Deletion. Histone-Lysine N-Methyltransferase. Humans. Interphase. Karyotyping / methods. Male. Myeloid-Lymphoid Leukemia Protein / genetics. Predictive Value of Tests. Prognosis. Proto-Oncogene Proteins c-ets / genetics. Repressor Proteins / genetics. Risk Factors. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845499.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / ETS translocation variant 6 protein; 0 / MLL protein, human; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Proteins c-ets; 0 / RUNX1 protein, human; 0 / Repressor Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


31. Ansari SH, Irfan M, Farzana, Panjwani VK, Shamsi TS: In-vivo purging with the anti-CD20 antibody rituximab along with standard allogeneic peripheral blood stem cell transplantation (PBSCT) for relapsed childhood pre-B acute lymphoblastic leukaemia (ALL). J Coll Physicians Surg Pak; 2006 Jan;16(1):67-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In-vivo purging with the anti-CD20 antibody rituximab along with standard allogeneic peripheral blood stem cell transplantation (PBSCT) for relapsed childhood pre-B acute lymphoblastic leukaemia (ALL).
  • He did not develop acute graft versus host disease (aGvHD) but localized chronic GvHD developed.

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16441995.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


32. Mukerji SS, Parmar H, Ibrahim M, Bradford C: An unusual cause of recurrent pediatric neck abscess: pyriform sinus fistula. Clin Imaging; 2007 Sep-Oct;31(5):349-51
MedlinePlus Health Information. consumer health - Abscess.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual cause of recurrent pediatric neck abscess: pyriform sinus fistula.
  • We present a case of recurrent anterior neck abscess due to a congenital fourth branchial anomaly.
  • This case reiterates that any child with a recurrent anterior neck mass should undergo thorough clinical and radiological assessments to rule out the possibility of a congenital sinus/fistula.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17825745.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Narchi H, Al-Hamdani M: First and recurrent pediatric urinary tract infections: do they have different antibiotic susceptibilities? J Chemother; 2008 Aug;20(4):472-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] First and recurrent pediatric urinary tract infections: do they have different antibiotic susceptibilities?
  • Antibiotic susceptibility studies in children rarely differentiate between first and recurrent urinary tract infections (UTI), although the latter, frequently associated with underlying urinary tract anomalies and antibiotic prophylaxis, are more likely to be associated with higher antibiotic resistance of uropathogens as a result.
  • We investigated whether antibiotic resistance was different between first and recurrent UTIs in 250 episodes (145 first and 105 recurrent) in 154 children (2 months to 12 years of age) with culture proven UTI.
  • The risk of resistance to other antibiotics was otherwise similar for first and recurrent UTIs.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Urinary Tract Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676228.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Gentamicins; O1R9FJ93ED / Cefuroxime
  •  go-up   go-down


34. O'Brien MM, Lacayo NJ, Lum BL, Kshirsagar S, Buck S, Ravindranath Y, Bernstein M, Weinstein H, Chang MN, Arceci RJ, Sikic BI, Dahl GV: Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2010 May;54(5):694-702
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.
  • As MDR1-mediated efflux of chemotherapeutic agents from leukemic blasts may contribute to drug resistance, a phase 1 study of valspodar combined with mitoxantrone and etoposide in pediatric patients with relapsed or refractory leukemias was performed.
  • Three of 11 patients with acute lymphoblastic leukemia (ALL) had complete responses while no patient with acute myeloid leukemia (AML) had an objective response.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Aug;14(8):1436-43 [10942240.001]
  • [Cites] Blood. 2007 May 15;109(10):4168-70 [17227830.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):832-42 [11157037.001]
  • [Cites] Leukemia. 2001 May;15(5):764-71 [11368437.001]
  • [Cites] Blood. 2001 Aug 15;98(4):988-94 [11493443.001]
  • [Cites] Hematol J. 2000;1(6):411-21 [11920222.001]
  • [Cites] Leukemia. 2002 May;16(5):920-7 [11986955.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):309-14 [11999562.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4377-85 [14645428.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3265-72 [15161679.001]
  • [Cites] J Histochem Cytochem. 1977 Jul;25(7):935-41 [894009.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(5):361-6 [2155063.001]
  • [Cites] Cancer Res. 1991 Sep 1;51(17):4665-70 [1873811.001]
  • [Cites] Cell. 1992 Oct 2;71(1):23-32 [1382860.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1635-42 [1403041.001]
  • [Cites] Anticancer Drugs. 1992 Dec;3(6):641-6 [1363199.001]
  • [Cites] Blood. 1993 May 1;81(9):2215-22 [8097632.001]
  • [Cites] Blood. 1996 Jun 1;87(11):4809-16 [8639853.001]
  • [Cites] Cancer Res. 1996 Jul 1;56(13):3010-20 [8674056.001]
  • [Cites] Blood. 1996 Jul 1;88(1):309-18 [8704189.001]
  • [Cites] Semin Hematol. 1997 Oct;34(4 Suppl 5):40-7 [9408960.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:118-45 [15561680.001]
  • [Cites] Leukemia. 2005 Feb;19(2):176-82 [15592433.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2320-6 [15788683.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1183-8 [15886328.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1315-24 [16254147.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4975-6; author reply 4976-7 [16754781.001]
  • [Cites] Curr Med Chem. 2006;13(16):1859-76 [16842198.001]
  • [Cites] Leuk Lymphoma. 2007 Apr;48(4):708-15 [17454628.001]
  • [Cites] Curr Opin Oncol. 2000 Sep;12(5):450-8 [10975553.001]
  • (PMID = 20209646.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA052168-12S1; United States / NCI NIH HHS / CA / U10 CA98413; United States / PHS HHS / / R01 52168; United States / NCI NIH HHS / CA / U10 CA098413; United States / NCRR NIH HHS / RR / M01 RR 00070; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA052168; United States / NCRR NIH HHS / RR / M01 RR000070; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclosporins; 0 / P-Glycoprotein; 121584-18-7 / valspodar; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone
  • [Other-IDs] NLM/ NIHMS155713; NLM/ PMC2838930
  •  go-up   go-down


35. Schrauder A, von Stackelberg A, Schrappe M, Cornish J, Peters C, ALL-BFM Study Group, EBMT PD WP, I-BFM Study Group: Allogeneic hematopoietic SCT in children with ALL: current concepts of ongoing prospective SCT trials. Bone Marrow Transplant; 2008 Jun;41 Suppl 2:S71-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Finally, the results of these prospective trials will determine the current potential of the different SCT procedures in HR or relapsed childhood ALL.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18545248.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


36. Schaad UB: OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review. World J Pediatr; 2010 Feb;6(1):5-12
PubMed Health. DARE review .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] OM-85 BV, an immunostimulant in pediatric recurrent respiratory tract infections: a systematic review.
  • BACKGROUND: This study was conducted to assess the efficacy of OM-85 BV (Broncho-Vaxom) in the prevention of pediatric recurrent respiratory tract infections (RTIs).
  • Available evidence suggests that defining recurrent RTIs as >or=3 infections per fall-winter semester is both medically and epidemiologically justified.
  • Of the patients in the OM-85 BV treated population (n=435), 32% had recurrent RTIs (that is, >or=3 RTIs/6 months) vs. 58.2% in the placebo treated population (n=416; P<0.001).
  • CONCLUSIONS: This meta-analysis shows, as observed in several individual trials, that the population treated with OM-85 BV had significantly and consistently fewer cases of recurrent RTIs.
  • The data suggest that the effect is greater in patients at increased risk of recurrent RTIs.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20143206.001).
  • [ISSN] 1867-0687
  • [Journal-full-title] World journal of pediatrics : WJP
  • [ISO-abbreviation] World J Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Broncho-Vaxom; 0 / Cell Extracts
  • [Number-of-references] 44
  •  go-up   go-down


37. Hicks CL, von Baeyer CL, McGrath PJ: Online psychological treatment for pediatric recurrent pain: a randomized evaluation. J Pediatr Psychol; 2006 Aug;31(7):724-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Online psychological treatment for pediatric recurrent pain: a randomized evaluation.
  • OBJECTIVE: To evaluate the efficacy of a distance treatment delivered through Internet and telephone for pediatric recurrent pain.

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16093516.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


38. Peres E, Wood GW, Poulik J, Baynes R, Sood S, Abidi MH, Klein J, Bhambhani K, Dansey R, Abella E: High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors. Neuropediatrics; 2008 Jun;39(3):151-6
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
  • Pediatric patients with recurrent brain tumors have a poor prognosis and limited therapeutic options.
  • We investigated the use of high-dose chemotherapy with adoptive immunotherapy for recurrent brain tumors.
  • Three pediatric patients with recurrent brain tumors received high-dose chemotherapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991194.001).
  • [ISSN] 0174-304X
  • [Journal-full-title] Neuropediatrics
  • [ISO-abbreviation] Neuropediatrics
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Antigens, CD3; 0 / Cancer Vaccines
  •  go-up   go-down


39. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL: Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. J Clin Oncol; 2008 Aug 20;26(24):3971-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].
  • PURPOSE: Treatment of childhood relapsed acute lymphoblastic leukemia (ALL) remains a significant challenge.
  • CONCLUSION: The AALL01P2 regimen is a tolerable and active reinduction platform, suitable for testing in combination with novel agents in B-precursor ALL.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Sep 1;96(5):1709-15 [10961868.001]
  • [Cites] Med Pediatr Oncol. 2000 May;34(5):313-8 [10797352.001]
  • [Cites] Lancet. 2001 Oct 13;358(9289):1239-41 [11675066.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):741-7 [12181040.001]
  • [Cites] Leukemia. 2002 Sep;16(9):1668-72 [12200679.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1566-72 [12886244.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Leukemia. 2004 Mar;18(3):499-504 [14981525.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1980 Jun 15;45(12):3090-4 [6930318.001]
  • [Cites] J Clin Oncol. 1985 Jul;3(7):998-1004 [3860629.001]
  • [Cites] Blood. 1988 Oct;72(4):1286-92 [3167209.001]
  • [Cites] Blood. 1991 Sep 1;78(5):1166-72 [1878583.001]
  • [Cites] Blood. 1993 Feb 1;81(3):602-9 [8427957.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):470-6 [8341213.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):34-8 [7743235.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Blood. 1996 Aug 1;88(3):831-7 [8704238.001]
  • [Cites] Med Pediatr Oncol. 1996 Dec;27(6):505-14 [8888809.001]
  • [Cites] Br J Haematol. 1997 Dec;99(3):671-7 [9401083.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4072-9 [9834212.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7942-50 [16258094.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3150-6 [16717292.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5750-62 [17179109.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] J Clin Oncol. 2008 Aug 1;26(22):3756-62 [18669463.001]
  • [Cites] Pediatr Blood Cancer. 2004 Oct;43(5):571-9 [15382275.001]
  • [Cites] Haematologica. 2000 Nov;85(11 Suppl):47-53 [11268324.001]
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [ErratumIn] J Clin Oncol. 2008 Oct 1;26(28): 4697.
  • (PMID = 18711187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21CA110344; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VB0R961HZT / Prednisone; ZRP63D75JW / Idarubicin
  • [Other-IDs] NLM/ PMC2654313
  •  go-up   go-down


40. High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, Vikstrom IB, Roberts AW, Lock RB: The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol; 2010 Mar;77(3):483-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs.
  • We show that ABT-737 was effective as a single agent against a panel of pediatric acute lymphoblastic leukemia (ALL) xenografts, previously established, from patient biopsies, in immunodeficient mice.
  • Although in vitro resistance of leukemia cell lines correlated with expression of the prosurvival protein Mcl-1, there was no relationship between Mcl-1 expression and in vivo xenograft response to ABT-737.
  • Rational targeting of specific components of the apoptotic pathway may be a useful approach to improve the treatment of refractory or relapsed pediatric ALL.
  • Overall, this study supports the inclusion of the clinical derivative of ABT-737, ABT-263 (for structure, see Cancer Res 68:3421-3428, 2008), into clinical trials against relapsed/refractory pediatric ALL.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Apoptosis / drug effects. Biphenyl Compounds / administration & dosage. Drug Delivery Systems / methods. Molecular Mimicry. Nitrophenols / administration & dosage. Pharmaceutical Preparations / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Sulfonamides / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Medicines.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038611.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT-737; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Nitrophenols; 0 / Pharmaceutical Preparations; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfonamides
  •  go-up   go-down


41. Chung BJ, Akst LM, Koltai PJ: 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol; 2006 Nov;70(11):1911-7
Hazardous Substances Data Bank. CIDOFOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis.
  • OBJECTIVES: Intralesional injection of cidofovir has been described as an adjunctive treatment for pediatric recurrent respiratory papillomatosis (RRP).
  • METHODS: Eleven pediatric patients originally treated with a standardized stepped-dose protocol of intralesional cidofovir for RRP were followed for an extended observational period.
  • Two patients initially achieved remission but have subsequently required additional treatment for recurrent disease.

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919339.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organophosphonates; 8J337D1HZY / Cytosine; JIL713Q00N / cidofovir
  •  go-up   go-down


42. Trautmann E, Kröner-Herwig B: A randomized controlled trial of Internet-based self-help training for recurrent headache in childhood and adolescence. Behav Res Ther; 2010 Jan;48(1):28-37
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of Internet-based self-help training for recurrent headache in childhood and adolescence.
  • Sixty-five children and adolescents (mean age: 12.7 years) with recurrent headache (at least 2 attacks per month) were each assigned to one of the three treatment conditions.
  • The results support the use of Internet programs for pediatric recurrent headache, especially given their accessibility and suitability for children and adolescents.

  • MedlinePlus Health Information. consumer health - Migraine.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19782343.001).
  • [ISSN] 1873-622X
  • [Journal-full-title] Behaviour research and therapy
  • [ISO-abbreviation] Behav Res Ther
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


43. Feltbower RG, Kinsey SE, Richards M, Shenton G, Michelagnoli MP, McKinney PA: Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UK. Br J Cancer; 2007 Apr 10;96(7):1147-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UK.
  • We examined population-based information on relapsed childhood haematological cancers, investigating factors that might influence both overall survival and survival following relapse among the 1177 children (0-14 years) diagnosed with a haematological malignancy in Yorkshire from 1974 to 2003, of whom 342 (29%) relapsed at least once.
  • Leukaemia patients from more deprived areas were significantly less likely to relapse (odds ratio=0.54, 95% confidence interval 0.32-0.93 for most deprived quintile vs least deprived quintile; P(trend)=0.06), especially those with acute myeloid leukaemia (P=0.04).
  • Overall, patients who relapsed at least once had 5-year survival rates of 46% (41-51%) compared with 79% (76-81%) of those who did not.
  • This provides a baseline for future comparisons and demonstrates that relapsed childhood cancer need not imply a poor outcome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2000 Mar;108(3):531-43 [10759711.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2130-8 [16304572.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2247-56 [11187916.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2257-66 [11187917.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2267-75 [11187918.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2295-306 [11187921.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2307-20 [11187922.001]
  • [Cites] J Public Health Med. 1999 Dec;21(4):401-6 [11469361.001]
  • [Cites] Lancet. 2001 Aug 4;358(9279):385-7 [11502322.001]
  • [Cites] Br J Haematol. 2003 Nov;123(3):396-405 [14616997.001]
  • [Cites] Acta Paediatr Scand. 1987 Sep;76(5):781-8 [3477938.001]
  • [Cites] Br J Cancer. 1990 Nov;62(5):806-15 [2173943.001]
  • [Cites] Med Pediatr Oncol. 1992;20(4):315-20 [1318996.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):162-6 [8044095.001]
  • [Cites] Med Pediatr Oncol. 1995 Nov;25(5):372-8 [7674994.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1717-26 [9351539.001]
  • [Cites] Br J Haematol. 1998 Jul;102(2):423-38 [9695956.001]
  • [Cites] BMJ. 1999 Mar 27;318(7187):843-4 [10092262.001]
  • [Cites] Br J Haematol. 2005 Jul;130(1):67-75 [15982346.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2025-9 [16304569.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2090-100 [16304571.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2205-22 [11187912.001]
  • (PMID = 17342086.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2360123
  •  go-up   go-down


44. Kano H, Yang HC, Kondziolka D, Niranjan A, Arai Y, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas. J Neurosurg Pediatr; 2010 Nov;6(5):417-23
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiosurgery for pediatric recurrent intracranial ependymomas.
  • OBJECT: To evaluate the role of stereotactic radiosurgery (SRS) in patients with recurrent or residual intracranial ependymomas after resection and fractionated radiation therapy (RT), the authors assessed overall survival, distant tumor relapse, progression-free survival (PFS), and complications.
  • CONCLUSIONS: Stereotactic radiosurgery offers an additional option beyond repeat surgery or RT in pediatric patients with residual or recurrent ependymomas after initial management.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039163.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Kaspers GJ, Reinhardt D, Fleischhack G, Armendariz H, Stark B, Zwaan CM, Zimmermann M, Creutzig U: Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML. Pediatr Blood Cancer; 2006 Oct 15;47(5):539-42
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML.
  • BACKGROUND: The efficacy in pediatric acute myeloid leukemia (AML) of single-agent methotrexate (MTX) at a higher dose than previously applied, 1,000 mg/m2, given as a theoretically beneficial 36-hr continuous infusion, is unknown, but may be beneficial based on preclinical data.
  • PROCEDURE: We performed a therapeutic window study in children with first relapsed AML treated in four different countries.
  • By that time, another four patients had been enrolled, of which one patient with a late relapsed AML FAB type M7 showed a good response.
  • CONCLUSIONS: This study shows that single-agent MTX in the applied regimen in pediatric relapsed AML has limited efficacy.
  • However, it also demonstrates the feasibility of an international and therapeutic window phase II study in pediatric relapsed AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Methotrexate / therapeutic use


46. Jabbari S, Andolino D, Weinberg V, Missett BT, Law J, Wara WM, O'Donnell RJ, Matthay KK, DuBois SG, Goldsby R, Haas-Kogan DA: Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy. Int J Radiat Oncol Biol Phys; 2009 Sep 1;75(1):177-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of high risk and recurrent pediatric desmoids using radiation as a component of multimodality therapy.
  • PURPOSE: To evaluate the role of radiation therapy (RT) as a component of multimodality therapy for pediatric desmoids.
  • CONCLUSIONS: Local control is difficult to achieve in pediatric patients with desmoids.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410386.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Foreman NK, Schissel D, Le T, Strain J, Fleitz J, Quinones R, Giller R: A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors. J Neurooncol; 2005 Jan;71(2):181-7
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15690136.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


48. Apollonsky N, Lipton JM: Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol; 2009 Jan;31(1):53-6
Hazardous Substances Data Bank. CLADRIBINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have treated 5 patients with recurrent LCH with 2-CDA/Ara-C chemotherapy and closely followed immune and hematopoietic function.
  • These data suggest that 2-CDA /Ara-C, should be considered in resistant and relapsed pediatric patients with LCH with high-risk multiorgan involvement.

  • Genetic Alliance. consumer health - Histiocytosis.
  • Genetic Alliance. consumer health - Langerhans cell histiocytosis.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19125089.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 47M74X9YT5 / Cladribine
  •  go-up   go-down


49. Lech-Maranda E, Korycka A, Robak T: Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity. Mini Rev Med Chem; 2009 Jun;9(7):805-12
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phase I/II clinical studies revealed its efficacy in hematological malignancies, and in 2004 clofarabine was approved by the United States Food and Drug Administration for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia after at least two prior chemotherapy regimens.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19519505.001).
  • [ISSN] 1389-5575
  • [Journal-full-title] Mini reviews in medicinal chemistry
  • [ISO-abbreviation] Mini Rev Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Nucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 47
  •  go-up   go-down


50. Choi J, Foss F: Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia. Yale J Biol Med; 2006 Dec;79(3-4):169-72
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
  • Refractory T-lymphoblastic leukemia in adults has a poor prognosis in patients who relapse after allogeneic stem cell transplantation, and relatively few new agents have demonstrated activity.
  • Clofarabine is a novel nucleoside analog that has been associated with significant clinical activity in relapsed pediatric B-ALL.
  • We used low dose clofarabine and induced a remission in a patient who relapsed in the skin and marrow after allogeneic transplant and was refractory to nelarabine and report a near complete response, suggesting significant activity for low intermittent dose clofarabine in patients with relapsed T-cell leukemias.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4075-86 [15353542.001]
  • [Cites] Nat Rev Drug Discov. 2006 Oct;5(10):855-63 [17016426.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3396-403 [15908652.001]
  • [Cites] Mol Pharmacol. 2006 Jan;69(1):346-53 [16234483.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Clin Oncol. 2006 Apr 20;24(12):1917-23 [16622268.001]
  • [Cites] Cancer Res. 1991 May 1;51(9):2386-94 [1707752.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1167-73 [12637486.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2379-86 [12791647.001]
  • [Cites] Blood. 2004 Feb 1;103(3):784-9 [14551141.001]
  • (PMID = 17940627.001).
  • [ISSN] 1551-4056
  • [Journal-full-title] The Yale journal of biology and medicine
  • [ISO-abbreviation] Yale J Biol Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Other-IDs] NLM/ PMC1994805
  •  go-up   go-down


51. Petermann F, Schulte IE: [Functional abdominal pain in childhood]. Schmerz; 2009 Feb;23(1):79-85; quiz 86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Functional abdominal pain in childhood].
  • Functional abdominal pain is one of the most common types of recurrent pediatric pain.

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 2002 Jul;141(1):76-83 [12091855.001]
  • [Cites] Eur Child Adolesc Psychiatry. 2002 Jun;11(3):115-22 [12369770.001]
  • [Cites] Eur J Epidemiol. 2003;18(10):965-75 [14598927.001]
  • [Cites] Arch Dis Child. 1958 Apr;33(168):165-70 [13534750.001]
  • [Cites] Arch Pediatr Adolesc Med. 2007 Feb;161(2):131-7 [17283297.001]
  • [Cites] J Pediatr. 2001 Dec;139(6):838-43 [11743510.001]
  • [Cites] Acta Paediatr. 1993 Apr;82(4):400-3 [8318810.001]
  • [Cites] BMJ. 1998 Apr 18;316(7139):1196-200 [9552994.001]
  • [Cites] J Abnorm Child Psychol. 1991 Aug;19(4):379-94 [1757708.001]
  • [Cites] J Psychosom Res. 1984;28(3):185-8 [6545355.001]
  • [Cites] Gastroenterology. 2006 Apr;130(5):1377-90 [16678553.001]
  • [Cites] Cochrane Database Syst Rev. 2008 Jan 23;(1):CD003014 [18254012.001]
  • [Cites] Schmerz. 2000 Oct;14(5):346-50 [12800025.001]
  • [Cites] Pain. 2006 May;122(1-2):43-52 [16495006.001]
  • [Cites] Schmerz. 1997 Jun 13;11(3):148-57 [12799816.001]
  • [Cites] Pediatrics. 2006 Jan;117(1):54-9 [16396860.001]
  • [Cites] Clin Psychol Rev. 1997;17(2):145-66 [9140713.001]
  • [Cites] Pediatrics. 2005 Jul;116(1):46-50 [15995029.001]
  • [Cites] Gastroenterology. 2006 Apr;130(5):1527-37 [16678566.001]
  • [Cites] Pediatrics. 2004 Apr;113(4):817-24 [15060233.001]
  • [Cites] J Pediatr Psychol. 2002 Dec;27(8):689-98 [12403859.001]
  • [Cites] J Psychosom Res. 2001 Oct;51(4):559-62 [11595243.001]
  • (PMID = 19165505.001).
  • [ISSN] 1432-2129
  • [Journal-full-title] Schmerz (Berlin, Germany)
  • [ISO-abbreviation] Schmerz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Louthrenoo O, Ukarapol N, Wongsawasdi L: Psychosocial problems and childhood recurrent abdominal pain. J Med Assoc Thai; 2010 Dec;93(12):1379-84
MedlinePlus Health Information. consumer health - Abdominal Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychosocial problems and childhood recurrent abdominal pain.
  • OBJECTIVE: Recurrent abdominal pain (RAP) is a challenging problem in general pediatrics.
  • Psychosocial assessment was obtained by using a semi-structured interview and the Pediatric Symptom Checklist (PSC).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344799.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


53. Oda M, Isoyama K, Ito E, Inoue M, Tsuchida M, Kigasawa H, Kato K, Kato S: Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia. Int J Hematol; 2009 Apr;89(3):374-82
MedlinePlus Health Information. consumer health - Organ Donation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after cord blood transplantation from unrelated donor as a second hematopoietic stem cell transplantation for recurrent pediatric acute myeloid leukemia.
  • The Japan Cord Blood Bank Network (JCBBN) reports the treatment of 22 children with acute myeloid leukemia (AML) who received umbilical cord blood transplantation from unrelated donors (CBT) as their second hematopoietic stem cell transplantation (HSCT).
  • [MeSH-major] Cord Blood Stem Cell Transplantation. Hematopoietic Stem Cell Transplantation. Leukemia, Myeloid, Acute / surgery. Tissue Donors


54. Zhenchuk A, Lotfi K, Juliusson G, Albertioni F: Mechanisms of anti-cancer action and pharmacology of clofarabine. Biochem Pharmacol; 2009 Dec 1;78(11):1351-9
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the past decade this is the only drug granted approval for treatment of pediatric acute leukemia.
  • Recent clinical studies have established the efficacy of clofarabine in treating malignancies with a poor prognosis, such as adult, elderly, and relapsed pediatric leukemia.
  • Due to this broad cytotoxicity, this drug is effective against various subtypes of leukemia and is currently being tested as an oral formulation and for combination therapy of both leukemias and solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19576186.001).
  • [ISSN] 1873-2968
  • [Journal-full-title] Biochemical pharmacology
  • [ISO-abbreviation] Biochem. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  • [Number-of-references] 77
  •  go-up   go-down


55. Clifton MS, Pelayo JC, Cortes RA, Grethel EJ, Wagner AJ, Lee H, Harrison MR, Farmer DL, Nobuhara KK: Surgical treatment of childhood recurrent pancreatitis. J Pediatr Surg; 2007 Jul;42(7):1203-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of childhood recurrent pancreatitis.
  • BACKGROUND/PURPOSE: Surgical intervention that improves pancreatic ductal drainage is a reasonable treatment strategy for recurrent pancreatitis in children.

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618881.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Zeidan A, Wang ES, Wetzler M: Pegasparaginase: where do we stand? Expert Opin Biol Ther; 2009 Jan;9(1):111-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The use of unmodified asparaginases (ASP) in the management of pediatric and adult acute lymphoblastic leukemia (ALL) is well established.
  • Clinical trials have demonstrated the efficacy, safety and tolerability of PEG-ASP administered intramuscularly, subcutaneously or intravenously as part of multi-agent chemotherapy regimens in the management of newly diagnosed and relapsed pediatric and adult ALL.
  • [MeSH-minor] Animals. Asparagine / metabolism. Clinical Trials as Topic. Drug Hypersensitivity / etiology. Drug Resistance, Neoplasm. Humans. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19063697.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / pegaspargase; 30IQX730WE / Polyethylene Glycols; 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase
  • [Number-of-references] 69
  •  go-up   go-down


57. Kuiper RP, Schoenmakers EF, van Reijmersdal SV, Hehir-Kwa JY, van Kessel AG, van Leeuwen FN, Hoogerbrugge PM: High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression. Leukemia; 2007 Jun;21(6):1258-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.
  • Gross cytogenetic anomalies are traditionally being used as diagnostic, prognostic and therapeutic markers in the clinical management of cancer, including childhood acute lymphoblastic leukemia (ALL).
  • Therefore, we profiled the genomes of 40 childhood ALLs at high resolution.
  • Many of these lesions involved recurrent (partially) overlapping deletions and duplications, containing various established leukemia-associated genes, such as ETV6, RUNX1 and MLL.
  • [MeSH-major] Cell Cycle / genetics. Cell Differentiation / genetics. Genes, Neoplasm. Lymphocytes / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics


58. Al-Amry MA, Al-Amri A, Khan AO: Resolution of childhood recurrent corneal phlyctenulosis following eradication of an intestinal parasite. J AAPOS; 2008 Feb;12(1):89-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of childhood recurrent corneal phlyctenulosis following eradication of an intestinal parasite.
  • Phlyctenular keratoconjunctivitis is a nodular foreign antigen delayed hypersensitivity reaction typically due to staphylococcal protein (but potentially secondary to antigen from a variety of different organisms, eg, mycobacteria and intestinal worms).(1-4) Conjunctival phlyctens are usually mild and transient, but corneal phlyctens can be severe and recurrent.(3,4) The subject of this report is a severe recurrent unilateral corneal case in a child whose stool was positive for Hymenolepsis nana.
  • Following treatment for the intestinal parasite, the child no longer suffered from recurrent ocular surface inflammation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083588.001).
  • [ISSN] 1528-3933
  • [Journal-full-title] Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
  • [ISO-abbreviation] J AAPOS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibodies, Helminth; 0 / Anticestodal Agents; 0 / Glucocorticoids; 0 / Ophthalmic Solutions
  •  go-up   go-down


59. Yang JJ, Bhojwani D, Yang W, Cai X, Stocco G, Crews K, Wang J, Morrison D, Devidas M, Hunger SP, Willman CL, Raetz EA, Pui CH, Evans WE, Relling MV, Carroll WL: Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia. Blood; 2008 Nov 15;112(10):4178-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.
  • The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown.
  • To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line.
  • EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827854318 for PMID:18768390 [PharmGKB] .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Br J Haematol. 2005 Nov;131(4):447-56 [16281934.001]
  • [Cites] Br J Haematol. 2005 Dec;131(5):579-87 [16351633.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1339-48 [17046466.001]
  • [Cites] FASEB J. 2006 Dec;20(14):2600-2 [17077285.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1258-66 [17443227.001]
  • [Cites] Immunity. 2007 Jun;26(6):715-25 [17582344.001]
  • [Cites] Blood. 2007 Jul 15;110(2):632-9 [17371950.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):24-36 [18097462.001]
  • [Cites] Nature. 2008 May 1;453(7191):110-4 [18408710.001]
  • [Cites] Cell Cycle. 2008 May 15;7(10):1315-20 [18418081.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5477-85 [18388178.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4629-31 [12036898.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):31-8 [12538346.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1573-82 [12886245.001]
  • [Cites] Oncogene. 2003 Oct 9;22(44):6970-6 [14534546.001]
  • [Cites] Ann Hematol. 2004;83 Suppl 1:S124-6 [15124703.001]
  • [Cites] Nature. 2004 Jun 24;429(6994):891-5 [15215866.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):139-50 [15324697.001]
  • [Cites] Mutagenesis. 2004 Sep;19(5):409-12 [15388815.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Blood. 1995 Nov 15;86(10):3861-8 [7579354.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2380-5 [10090949.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):368-76 [15599932.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • (PMID = 18768390.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / U01 CA114762; United States / NCI NIH HHS / CA / NCI CA 51 001; United States / NIGMS NIH HHS / GM / U01GM61374; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NIGMS NIH HHS / GM / U01 GM061374; United States / NCI NIH HHS / CA / CA 78 224; United States / NCI NIH HHS / CA / R01 CA093552; United States / NCI NIH HHS / CA / CA093552-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Hormonal; 0 / DNA-Binding Proteins; 0 / EBF1 protein, human; 0 / G-T mismatch-binding protein; 0 / IKZF1 protein, human; 0 / Neoplasm Proteins; 0 / Trans-Activators; 148971-36-2 / Ikaros Transcription Factor; 9PHQ9Y1OLM / Prednisolone; E7WED276I5 / 6-Mercaptopurine
  • [Other-IDs] NLM/ PMC2581992
  •  go-up   go-down


60. Bryson PC, Leight WD, Zdanski CJ, Drake AF, Rose AS: High-resolution ultrasound in the evaluation of pediatric recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg; 2009 Mar;135(3):250-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution ultrasound in the evaluation of pediatric recurrent respiratory papillomatosis.
  • PARTICIPANTS: Eight patients (4 females and 4 males) with recurrent respiratory papillomatosis, with a mean age of 10.25 years and a mean of 14 surgical papilloma resections (range, 3-35).
  • MAIN OUTCOME MEASURES: The ultrasonographic appearance of respiratory papillomas and pediatric airway anatomy.
  • CONCLUSIONS: Recurrent respiratory papillomas have a characteristic ultrasonographic appearance that seems to correlate with endoscopic findings.
  • Although direct laryngoscopy and bronchoscopy are the criterion standard, airway ultrasound may have a role in the early diagnosis of, surveillance of, and operative planning for recurrent respiratory papillomatosis.

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289702.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Domínguez Hinarejos C, Bonillo García MA, Alapont Alacreu JM, Serrano Durbá A, Estornell Moragues F, García Ibarra F: [Assesmment urethrorrhagia in childhood]. Actas Urol Esp; 2007 Jan;31(1):29-32
MedlinePlus Health Information. consumer health - Urethral Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Assesmment urethrorrhagia in childhood].
  • CONCLUSIONS: Urethrorrhagia in childhood is a benign condition in most cases, which is almost always cured spontaneously during the first 2 years of follow-up.
  • Radiological studies as well as endoscopic procedures are unnecessary in the early management of these patients thus being relegated to recurrent or persistent bleeding.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410983.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


62. Fazekas T, Wiesbauer P, Schroth B, Pötschger U, Gadner H, Heitger A: Selective IgA deficiency in children with recurrent parotitis of childhood. Pediatr Infect Dis J; 2005 May;24(5):461-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective IgA deficiency in children with recurrent parotitis of childhood.
  • Recurrent parotitis of childhood is defined as the relapsing form of juvenile (idiopathic) parotitis and represents a rare inflammatory disorder of the parotid gland with potentially significant morbidity.

  • Genetic Alliance. consumer health - Selective IgA deficiency.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15876950.001).
  • [ISSN] 0891-3668
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Grodman H, Wolfe L, Kretschmar C: Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue. Pediatr Blood Cancer; 2009 Jul;53(1):33-6
Hazardous Substances Data Bank. THIO-TEPA .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with recurrent medulloblastoma or central nervous system germinoma treated with low dose continuous intravenous etoposide along with dose-intensive chemotherapy followed by autologous hematopoietic stem cell rescue.
  • BACKGROUND: Adults and children with recurrent malignant central nervous system (CNS) tumors have a poor prognosis despite high dose chemotherapy with a conventional stem cell rescue regimen.
  • In this study we evaluated the results of low dose, continuous infusion etoposide over 21 days added to a conventional high-dose regimen of carboplatin and thiotepa in eight patients with relapsed pediatric CNS tumors.
  • RESULTS: Eight adults and children, with a mean age of 12.9 years (age range 5.6-27.8 years), with relapsed primary CNS tumors (metastatic medulloblastoma (7), germinoma (1)), were enrolled.
  • CONCLUSION: The strategy of low dose chronic exposure to a topoisomerase inhibitor along with ablative carboplatin and thiotepa with stem cell rescue showed promising survival outcomes in these relapsed patients.
  • This treatment strategy deserves further evaluation in a larger group of high-risk or relapsed primary CNS tumors.

  • Genetic Alliance. consumer health - Germinoma.
  • Genetic Alliance. consumer health - Medulloblastoma.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Wiley-Liss, Inc.
  • (PMID = 19326417.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 905Z5W3GKH / Thiotepa; BG3F62OND5 / Carboplatin
  •  go-up   go-down


64. Don M, Fasoli L, Gregorutti V, Pisa F, Valent F, Prodan M, Canciani M: Recurrent respiratory infections and phagocytosis in childhood. Pediatr Int; 2007 Feb;49(1):40-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent respiratory infections and phagocytosis in childhood.
  • BACKGROUND: About 10% of pre-school children has recurrent respiratory infections (RRI), which could be related to environmental and/or immunological factors.
  • The aim of the present study has been to evaluate the impact of phagocytosis (FAG) and reactive oxygen intermediates (ROI) production deficiencies on pediatric RRI by the measurement of FAG and ROI activity of the polymorphonuclear neutrophils.
  • METHODS: Serum immunoglobulins, IgG subclasses, lymphocytic subpopulations, FAG and ROI tests were measured in 90 children with RRI, in a moment of well-being and off all medications for at least 4 weeks.
  • CONCLUSIONS: The authors' results permit only to suppose an etiological role of FAG and ROI deficiencies of polymorphonuclear neutrophils in the genesis of pediatric RRI, irrespective of the age of the patients, and further studies are necessary for confirmation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17250504.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Reactive Oxygen Species
  •  go-up   go-down


65. Plouin-Gaudon I, Bossard D, Fuchsmann C, Ayari-Khalfallah S, Froehlich P: Diffusion-weighted MR imaging for evaluation of pediatric recurrent cholesteatomas. Int J Pediatr Otorhinolaryngol; 2010 Jan;74(1):22-6
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MR imaging for evaluation of pediatric recurrent cholesteatomas.
  • OBJECTIVE: To compare the efficiency of diffusion-weighted MR imaging (MRI) vs. high resolution CT in predicting recurrent or residual cholesteatoma in children who underwent prior middle ear surgery.
  • Diagnosis of recurrent cholesteatoma was based on the evidence of a hyperintense image at B1000 on diffusion-weighted images.
  • CONCLUSION: Diffusion-weighted MRI is associated with a high positive predictive value for the detection of recurrent cholesteatoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19889465.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


66. Wagner-Bohn A, Paulussen M, Vieira Pinheiro JP, Gerss J, Stoffregen C, Boos J: Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin. Anticancer Drugs; 2006 Aug;17(7):859-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The therapeutic benefit and side-effect profile of gemcitabine in adults with relapsed solid tumors is well known.
  • So far, few data are available about its significance in pediatric relapsed solid tumors.
  • To determine the efficacy and tolerability of gemcitabine in children, the drug was administered by intravenous short-term infusion over 30 min at a dose of 1200 mg/m2 weekly for 3 weeks as one cycle in children with relapsed solid tumor of embryonic or mesenchymal origin.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926636.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


67. Picas-Jufresa A, Lladó-Puigdemont A, Buñuel-Alvarez JC, Vila-Pablos C: [Recurrent community acquired pneumonia in young children: risk factor for the development of childhood asthma?]. Aten Primaria; 2006 Feb 28;37(3):127-31; discussion 131-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent community acquired pneumonia in young children: risk factor for the development of childhood asthma?].
  • OBJECTIVE: To determine if recurrent community acquired pneumonia (RP) is a risk factor for developing childhood asthma (CA), compared with those children who only suffer one episode of pneumonia or non-recurrent pneumonia (NRP).
  • PRINCIPAL MEASUREMENTS: The relative risk (RR) and confidence interval (95% CI) of childhood asthma in the presence of recurrent pneumonia as compared to non-recurrent pneumonia, and the RR of recurrent pneumonia in the presence of childhood asthma.


68. Kumar RA, KaraMohamed S, Sudi J, Conrad DF, Brune C, Badner JA, Gilliam TC, Nowak NJ, Cook EH Jr, Dobyns WB, Christian SL: Recurrent 16p11.2 microdeletions in autism. Hum Mol Genet; 2008 Feb 15;17(4):628-38
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent 16p11.2 microdeletions in autism.
  • Autism is a childhood neurodevelopmental disorder with a strong genetic component, yet the identification of autism susceptibility loci remains elusive.
  • We discovered a recurrent 16p11.2 microdeletion in two probands with autism and none in controls.
  • Our work reports the first frequency, breakpoint, bioinformatic and phenotypic analyses of a de novo 16p11.2 microdeletion that represents one of the most common recurrent genomic disorders associated with autism to date.

  • Genetic Alliance. consumer health - Autism.
  • Genetics Home Reference. consumer health - chromosome 16.
  • Genetics Home Reference. consumer health - 16p11.2 deletion syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156158.001).
  • [ISSN] 1460-2083
  • [Journal-full-title] Human molecular genetics
  • [ISO-abbreviation] Hum. Mol. Genet.
  • [Language] eng
  • [Grant] United States / NIMH NIH HHS / MH / 1R01MH64547-01; United States / NINDS NIH HHS / NS / 1R01NS51812; United States / NIMH NIH HHS / MH / MH64547
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers
  •  go-up   go-down


69. Meyer T, Höcht B: Recurrent laryngeal nerve monitoring during thyroid surgery in childhood. Eur J Pediatr Surg; 2006 Jun;16(3):149-54
MedlinePlus Health Information. consumer health - Thyroid Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent laryngeal nerve monitoring during thyroid surgery in childhood.
  • INTRODUCTION: Diseases of the thyroid gland are one of the most common endocrinopathies in childhood.
  • But if surgical treatment is carried out, intraoperative damage of the recurrent laryngeal nerve (RLN) is a common and severe complication.
  • Intraoperative identification and functional control of the recurrent nerve was performed using the Neurosign 100, placing a needle electrode transligamentously into the vocal muscle.
  • Therefore, IOM of the RLN could develop into a helpful and easy method for the prevention of intraoperative damage of the recurrent laryngeal nerve during thyroid surgery in childhood.
  • [MeSH-major] Monitoring, Intraoperative. Recurrent Laryngeal Nerve. Thyroid Diseases / surgery. Thyroidectomy / methods
  • [MeSH-minor] Adolescent. Child. Electric Stimulation / instrumentation. Equipment Design. Female. Humans. Intraoperative Complications / prevention & control. Male. Recurrent Laryngeal Nerve Injuries. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909351.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


70. Heng JL, Chen YC, Quah TC, Liu TC, Yeoh AE: Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006. Ann Acad Med Singapore; 2010 Feb;39(2):102-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedicated cytogenetics factor is critical for improving karyotyping results for childhood leukaemias - experience in the National University Hospital, Singapore 1989-2006.
  • INTRODUCTION: Childhood leukaemia accounts for more than 40% of new childhood cancer cases.
  • Unfortunately, karyotyping of childhood leukaemia is difficult, laborious and often unsuccessful.
  • Among them, 369 newly diagnosed and relapsed childhood acute leukaemia cases [281 acute lymphoblastic leukaemia (ALL) and 88 acute myeloid leukaemia (AML)] have been diagnosed at NUH.
  • [MeSH-major] Cytogenetic Analysis / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20237730.001).
  • [ISSN] 0304-4602
  • [Journal-full-title] Annals of the Academy of Medicine, Singapore
  • [ISO-abbreviation] Ann. Acad. Med. Singap.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


71. Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, Berger B, Neefe JR: HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol; 2005 Sep;114(9):730-7
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial.
  • OBJECTIVES: We sought to evaluate the effectiveness of HspE7, a recombinant fusion protein of Hsp65 from Mycobacterium bovis BCG and E7 protein from human papillomavirus 16, to improve the clinical course of pediatric patients with recurrent respiratory papillomatosis.
  • Twenty-seven male and female patients with recurrent respiratory papillomatosis, ages 2 to 18 years, were enrolled and followed up to 60 weeks.
  • CONCLUSIONS: Treatment with HspE7 appears to significantly improve the clinical course in pediatric patients with RRP insofar as it reduces the frequency of required surgeries.

  • Genetic Alliance. consumer health - Recurrent respiratory papillomatosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240938.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / Chaperonin 60; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / Recombinant Fusion Proteins; 0 / heat-shock protein 65, Mycobacterium; 0 / oncogene protein E7, Human papillomavirus type 16; EC 3.6.1.- / Chaperonins
  •  go-up   go-down


72. Bungaro S, Dell'Orto MC, Zangrando A, Basso D, Gorletta T, Lo Nigro L, Leszl A, Young BD, Basso G, Bicciato S, Biondi A, te Kronnie G, Cazzaniga G: Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks. Genes Chromosomes Cancer; 2009 Jan;48(1):22-38
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integration of genomic and gene expression data of childhood ALL without known aberrations identifies subgroups with specific genetic hallmarks.
  • Pediatric acute lymphoblastic leukemia (ALL) comprises genetically distinct subtypes.
  • To identify genomic aberrancies in childhood ALL patients nonclassifiable by conventional methods, we performed a single nucleotide polymorphisms (SNP) array-based genomic analysis of leukemic cells from 29 cases.
  • To identify variation in expression of genes directly or indirectly affected by recurrent genomic alterations, we integrated genomic and gene expression data generated by microarray analyses of the same samples.
  • [MeSH-major] Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18803328.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Calcium-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Genetic Markers; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / PAX5 protein, human; 0 / Proto-Oncogene Proteins c-ets; 0 / Repressor Proteins; 0 / Smad1 Protein; 134324-36-0 / Serrate proteins
  •  go-up   go-down


73. Wall SR, Wat D, Spiller OB, Gelder CM, Kotecha S, Doull IJ: The viral aetiology of croup and recurrent croup. Arch Dis Child; 2009 May;94(5):359-60
MedlinePlus Health Information. consumer health - Croup.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The viral aetiology of croup and recurrent croup.
  • BACKGROUND: Historically croup was subdivided into classic "viral" croup with associated viral upper respiratory tract infections, and recurrent or spasmodic croup where asthma and allergies were thought more important.
  • Recurrent croup was defined as at least one other admission for croup in the preceding or following 3 years.
  • There was no significant difference in the rate of virus detection between those with single episode croup and recurrent croup.
  • CONCLUSIONS: The aetiologies of viral and recurrent croup appear similar.
  • [MeSH-minor] Acute Disease. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Prospective Studies. RNA, Viral. Recurrence. Respiratory Tract Infections / virology. Reverse Transcriptase Polymerase Chain Reaction. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801765.001).
  • [ISSN] 1468-2044
  • [Journal-full-title] Archives of disease in childhood
  • [ISO-abbreviation] Arch. Dis. Child.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


74. Chitkara DK, Rawat DJ, Talley NJ: The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. Am J Gastroenterol; 2005 Aug;100(8):1868-75
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review.
  • OBJECTIVE: Recurrent abdominal pain (RAP) of childhood is a common problem encountered by clinicians.
  • The aim of this study was to systematically review published literature about the prevalence, incidence, natural history, and co-morbid conditions of childhood RAP in western countries.
  • In addition, childhood RAP was reported to be associated with psychological co-morbidity in childhood and adulthood.
  • CONCLUSION: RAP is a common complaint of childhood with associated familial, psychological, and co-morbid conditions.

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16086724.001).
  • [ISSN] 0002-9270
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 64
  •  go-up   go-down


75. Kværner KJ, Kristiansen HA, Russell MB: Otitis media history, surgery and allergy in 60-year perspective: a population-based study. Int J Pediatr Otorhinolaryngol; 2010 Dec;74(12):1356-60
MedlinePlus Health Information. consumer health - Ear Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To assess the relationship between recurrent otitis media (OM), OM surgery and allergy in a 60-years perspective in the general population.
  • Main outcome measures were recurrent childhood OM, childhood myringotomy, ventilation tubes or adenoidectomy and lifetime allergy.
  • RESULTS: The prevalence of recurrent OM was 24.3% (n=4823) and OM surgery 12.4% (n=2499).
  • Recurrent OM and OM surgery was more common in respondents with allergy.
  • CONCLUSIONS: Despite a twofold increase in recurrent OM and OM surgery from 1925 to 1945, the proportion of OM and OM surgery have been stable since 1945.
  • Our findings suggest a shift in clinical practice, most likely indicating a change in surgery from acute infections to otitis media with effusion (OME).

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20934223.001).
  • [ISSN] 1872-8464
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


76. Uziel Y, Butbul-Aviel Y, Barash J, Padeh S, Mukamel M, Gorodnitski N, Brik R, Hashkes PJ: Recurrent transient synovitis of the hip in childhood. Longterm outcome among 39 patients. J Rheumatol; 2006 Apr;33(4):810-1
Genetic Alliance. consumer health - Synovitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent transient synovitis of the hip in childhood. Longterm outcome among 39 patients.
  • OBJECTIVE: To describe the outcome of children with recurrent transient synovitis (TS) of the hip.
  • RESULTS: We studied 39 children, 26 boys and 13 girls, from 6 pediatric rheumatology centers.
  • CONCLUSION: Children with recurrent TS usually have a benign course.
  • In some patients recurrent TS may be the presenting feature of a chronic inflammatory condition.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16583482.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


77. Stempak D, Gammon J, Halton J, Moghrabi A, Koren G, Baruchel S: A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol; 2006 Nov;28(11):720-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
  • This study evaluated the safety and pharmacokinetics of celecoxib and LDM vinblastine or cyclophosphamide in children with recurrent, refractory solid tumors.
  • We concluded that this regimen is well tolerated hence supporting the use of this form of therapy in pediatric patients.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • Hazardous Substances Data Bank. CELECOXIB .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17114958.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Biomarkers; 0 / Pyrazoles; 0 / Sulfonamides; 5V9KLZ54CY / Vinblastine; 8N3DW7272P / Cyclophosphamide; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


78. Kõljalg S, Truusalu K, Vainumäe I, Stsepetova J, Sepp E, Mikelsaar M: Persistence of Escherichia coli clones and phenotypic and genotypic antibiotic resistance in recurrent urinary tract infections in childhood. J Clin Microbiol; 2009 Jan;47(1):99-105
MedlinePlus Health Information. consumer health - Urinary Tract Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of Escherichia coli clones and phenotypic and genotypic antibiotic resistance in recurrent urinary tract infections in childhood.
  • We assessed the clonality of consecutive Escherichia coli isolates during the course of recurrent urinary tract infections (RUTI) in childhood in order to compare clonality with phenotypic antibiotic resistance patterns, the presence of integrons, and the presence of the sul1, sul2, and sul3 genes.
  • Altogether, 78 urinary E. coli isolates from 27 children, who experienced recurrences during a 1-year follow-up after the first attack of acute pyelonephritis, were investigated.

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Antimicrob Chemother. 2005 May;55(5):639-44 [15761064.001]
  • [Cites] J Antimicrob Chemother. 2006 Apr;57(4):666-72 [16464890.001]
  • [Cites] J Clin Microbiol. 2006 May;44(5):1776-81 [16672406.001]
  • [Cites] J Antimicrob Chemother. 2006 Aug;58(2):305-9 [16782743.001]
  • [Cites] Epidemiol Infect. 2006 Oct;134(5):1015-23 [16438745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14170-5 [16968784.001]
  • [Cites] Infect Immun. 2007 Jan;75(1):52-60 [17074856.001]
  • [Cites] Appl Environ Microbiol. 2007 May;73(10):3291-9 [17384307.001]
  • [Cites] J Antimicrob Chemother. 2007 Jul;60(1):92-9 [17540675.001]
  • [Cites] J Chemother. 2007 Jun;19(3):263-70 [17594920.001]
  • [Cites] JAMA. 2007 Jul 11;298(2):179-86 [17622599.001]
  • [Cites] Scand J Infect Dis. 2007;39(8):671-5 [17654342.001]
  • [Cites] PLoS Med. 2007 Dec;4(12):e329 [18092884.001]
  • [Cites] Pediatr Nephrol. 2008 Apr;23(4):597-602 [18193296.001]
  • [Cites] J Paediatr Child Health. 1999 Oct;35(5):454-9 [10571758.001]
  • [Cites] Acta Paediatr Suppl. 1999 Nov;88(431):31-9 [10588269.001]
  • [Cites] Am J Epidemiol. 2000 Jun 15;151(12):1194-205 [10905532.001]
  • [Cites] CMAJ. 2000 Sep 5;163(5):523-9 [11006762.001]
  • [Cites] Scand J Infect Dis. 2000;32(5):495-9 [11055653.001]
  • [Cites] Pediatr Nephrol. 2001 Jan;16(1):69-72 [11198607.001]
  • [Cites] Clin Infect Dis. 2001 Jun 1;32(11):1608-14 [11340533.001]
  • [Cites] Lancet. 2001 Apr 28;357(9265):1325-8 [11343738.001]
  • [Cites] Infect Immun. 2001 Jul;69(7):4572-9 [11402001.001]
  • [Cites] Scand J Infect Dis. 2001;33(5):333-8 [11440217.001]
  • [Cites] J Med Microbiol. 2001 Jul;50(7):650-2 [11444777.001]
  • [Cites] Antimicrob Agents Chemother. 2001 Sep;45(9):2658-61 [11502548.001]
  • [Cites] Clin Infect Dis. 2001 Nov 15;33(10):1682-6 [11595990.001]
  • [Cites] J Infect Dis. 2002 Feb 1;185(3):375-9 [11807720.001]
  • [Cites] Lancet Infect Dis. 2001 Sep;1(2):101-14 [11871461.001]
  • [Cites] J Urol. 2002 Aug;168(2):704-7; discussion 707 [12131355.001]
  • [Cites] J Clin Microbiol. 2002 Aug;40(8):3038-40 [12149373.001]
  • [Cites] J Infect Dis. 2002 Oct 1;186(7):1039-42 [12232848.001]
  • [Cites] J Antimicrob Chemother. 2002 Oct;50(4):513-6 [12356795.001]
  • [Cites] J Infect Dis. 2002 Dec 15;186(12):1852-6 [12447775.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):195-202 [12529459.001]
  • [Cites] Antimicrob Agents Chemother. 2003 Mar;47(3):1169-72 [12604565.001]
  • [Cites] Pediatr Nephrol. 2003 Apr;18(4):362-5 [12700963.001]
  • [Cites] Pediatr Res. 2003 Jul;54(1):8-14 [12700366.001]
  • [Cites] J Clin Microbiol. 2003 Dec;41(12):5429-33 [14662921.001]
  • [Cites] APMIS. 2004 Mar;112(3):159-64 [15153157.001]
  • [Cites] Acta Paediatr Scand. 1981 Nov;70(6):879-83 [7324941.001]
  • [Cites] Pediatr Nephrol. 1987 Oct;1(4):647-56 [3153346.001]
  • [Cites] Diagn Microbiol Infect Dis. 1994 Apr;18(4):263-5 [7924224.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Jan;39(1):185-91 [7695304.001]
  • [Cites] AJR Am J Roentgenol. 1995 May;164(5):1237-41 [7717238.001]
  • [Cites] J Infect Dis. 1995 Aug;172(2):440-5 [7622887.001]
  • [Cites] J Clin Microbiol. 1995 Sep;33(9):2233-9 [7494007.001]
  • [Cites] Clin Infect Dis. 1996 Jan;22(1):91-9 [8824972.001]
  • [Cites] J Urol. 1997 Mar;157(3):1127-9 [9072556.001]
  • [Cites] J Urol. 1997 Aug;158(2):566-8 [9224361.001]
  • [Cites] Pediatrics. 1999 Apr;103(4 Pt 1):843-52 [10103321.001]
  • [Cites] Clin Microbiol Infect. 2005 Mar;11(3):185-92 [15715715.001]
  • [Cites] Clin Microbiol Rev. 2005 Apr;18(2):417-22 [15831830.001]
  • (PMID = 18971357.001).
  • [ISSN] 1098-660X
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Bacterial
  • [Other-IDs] NLM/ PMC2620871
  •  go-up   go-down


79. Hospach T, Langendoerfer M, von Kalle T, Maier J, Dannecker GE: Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate. Eur J Pediatr; 2010 Sep;169(9):1105-11
MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal involvement in chronic recurrent multifocal osteomyelitis (CRMO) in childhood and effect of pamidronate.
  • There are only a few studies that address the frequency and type of spinal involvement in patients with chronic recurrent multifocal osteomyelitis (CRMO) as well as the outcome of these patients treated with pamidronate (PAM).

  • Genetic Alliance. consumer health - Chronic Recurrent Multifocal Osteomyelitis.
  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 2002 Aug;141(2):198-203 [12183714.001]
  • [Cites] Ann Rheum Dis. 2005 Feb;64(2):279-85 [15647436.001]
  • [Cites] Radiographics. 2004 Sep-Oct;24(5):1317-30 [15371611.001]
  • [Cites] Radiographics. 2009 Jul-Aug;29(4):1159-77 [19605663.001]
  • [Cites] J Rheumatol. 2003 Mar;30(3):430-4 [12610795.001]
  • [Cites] J Bone Joint Surg Br. 1993 Jul;75(4):582-91 [8331113.001]
  • [Cites] Rheumatology (Oxford). 2008 Sep;47(9):1397-9 [18621750.001]
  • [Cites] Joint Bone Spine. 2001 May;68(3):245-51 [11394625.001]
  • [Cites] J Pediatr Orthop. 2002 Jul-Aug;22(4):501-5 [12131448.001]
  • [Cites] J Rheumatol. 2007 Jul;34(7):1585-9 [17611964.001]
  • [Cites] J Bone Joint Surg Am. 1989 Jan;71(1):105-12 [2643605.001]
  • [Cites] Skeletal Radiol. 1997 Apr;26(4):230-8 [9151372.001]
  • [Cites] Rheumatology (Oxford). 2004 Oct;43(10):1246-51 [15238641.001]
  • [Cites] J Pediatr. 2008 Apr;152(4):571-5 [18346517.001]
  • [Cites] Skeletal Radiol. 2003 Jun;32(6):328-36 [12761599.001]
  • [Cites] Pediatr Infect Dis J. 1987 Oct;6(10):907-11 [3696821.001]
  • [Cites] Pediatr Rheumatol Online J. 2009 Jan 12;7:2 [19138427.001]
  • [Cites] J Bone Miner Res. 2005 Jul;20(7):1235-43 [15940378.001]
  • [Cites] Bone. 2007 Sep;41(3):366-70 [17574945.001]
  • [Cites] Rofo. 2002 Oct;174(10 ):1236-42 [12375195.001]
  • [Cites] Clin Radiol. 2004 Oct;59(10):881-91 [15451346.001]
  • [Cites] Joint Bone Spine. 2007 Jan;74(1):32-8 [17196868.001]
  • [Cites] Bone. 2006 Oct;39(4):901-6 [16730480.001]
  • [Cites] J Pediatr. 2009 Jan;154(1):154-5; author reply 155 [19187751.001]
  • [Cites] J Rheumatol. 2008 Apr;35(4):707-12 [18381777.001]
  • [Cites] J Rheumatol. 2000 May;27(5):1318-9 [10813311.001]
  • [Cites] J Rheumatol. 2001 Jan;28(1):144-55 [11196517.001]
  • [Cites] Eur Spine J. 2008 Sep;17 Suppl 2:S248-52 [17912555.001]
  • [Cites] AJR Am J Roentgenol. 1988 Jul;151(1):142-4 [3259798.001]
  • [Cites] Curr Opin Rheumatol. 2007 Jul;19(4):340-5 [17551363.001]
  • [Cites] Semin Musculoskelet Radiol. 2004 Sep;8(3):243-53 [15478027.001]
  • [Cites] J Belge Radiol. 1998 Apr;81(2):84-6 [9640874.001]
  • [Cites] Semin Arthritis Rheum. 1999 Dec;29(3):159-71 [10622680.001]
  • [Cites] Ann Radiol (Paris). 1972 Mar-Apr;15(3):329-42 [4403064.001]
  • [Cites] Pediatrics. 2005 Nov;116(5):1231-3 [16264014.001]
  • [Cites] Arthritis Rheum. 2003 May;48(5):1467; author reply 1467-8 [12746931.001]
  • [Cites] J Bone Joint Surg Br. 1980 Aug;62(3):376-80 [7410472.001]
  • [Cites] Ann Rheum Dis. 2002 Apr;61(4):375-6 [11874849.001]
  • [Cites] Rheumatology (Oxford). 2007 Jan;46(1):154-60 [16782988.001]
  • [Cites] Arthritis Rheum. 2002 Jul;46(7):1965-8 [12124882.001]
  • (PMID = 20339868.001).
  • [ISSN] 1432-1076
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


80. Chang CH, Hsu YH: Hyper-IgE syndrome with Epstein-Barr virus associated extranodal NK/T cell lymphoma of skin. Kaohsiung J Med Sci; 2010 Apr;26(4):206-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report an 18-year-old woman who was frequently hospitalized since childhood because of recurrent pneumonia and urinary tract infection.
  • A skin biopsy showed angiocentric and angiodestructive atypical lymphoid infiltration.
  • In situ hybridization revealed latent Epstein- Barr virus-infected lymphoid cells.

  • Genetic Alliance. consumer health - MYH9 related thrombocytopenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20434102.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


81. Lentrodt S, Lentrodt J, Kübler N, Mödder U: Hyperbaric oxygen for adjuvant therapy for chronically recurrent mandibular osteomyelitis in childhood and adolescence. J Oral Maxillofac Surg; 2007 Feb;65(2):186-91
Genetic Alliance. consumer health - Osteomyelitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperbaric oxygen for adjuvant therapy for chronically recurrent mandibular osteomyelitis in childhood and adolescence.
  • PURPOSE: In this article, the question of whether adjuvant hyperbaric oxygen therapy (HBO) has a positive effect when treating chronically recurrent mandibular osteomyelitis in children and adolescents is discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236919.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Siegel MJ, Finlay JL, Zacharoulis S: State of the art chemotherapeutic management of pediatric brain tumors. Expert Rev Neurother; 2006 May;6(5):765-79
MedlinePlus Health Information. consumer health - Children's Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] State of the art chemotherapeutic management of pediatric brain tumors.
  • CNS tumors are the most common solid tumor of childhood.
  • This article will review current treatments for pediatric brain tumors; low-grade gliomas, high-grade gliomas, medulloblastomas and ependymomas.
  • It will also highlight the treatments that are used for brain tumors in very young children and in children with recurrent brain tumors.
  • The management of recurrent pediatric brain tumors unresponsive to standard therapy will be discussed.
  • Future directions of therapy for pediatric brain tumors are described.
  • Finally, the future direction of pediatric neuro-oncology and the focus of the field as it battles pediatric brain tumors is discussed.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734524.001).
  • [ISSN] 1744-8360
  • [Journal-full-title] Expert review of neurotherapeutics
  • [ISO-abbreviation] Expert Rev Neurother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 165
  •  go-up   go-down


83. Wirrell E, Farrell K, Whiting S: The epileptic encephalopathies of infancy and childhood. Can J Neurol Sci; 2005 Nov;32(4):409-18
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epileptic encephalopathies of infancy and childhood.
  • The epileptic encephalopathies comprise a group of devastating seizure syndromes which begin in infancy and early childhood and usually result in intractable epilepsy.
  • In these "idiopathic" cases, recurrent subtle seizures, frequent epileptiform discharge and non-convulsive status epilepticus probably all play a role in deterioration of cognitive function and evolution of behavior disorders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16408569.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / Immunoglobulins, Intravenous; 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 117
  •  go-up   go-down


84. Bernard TJ, deVeber GA, Benke TA: Athletic participation after acute ischemic childhood stroke: a survey of pediatric stroke experts. J Child Neurol; 2007 Aug;22(8):1050-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Athletic participation after acute ischemic childhood stroke: a survey of pediatric stroke experts.
  • Minimal evidence exists about the risk of recurrent childhood acute ischemic stroke in patients subjected to a subsequent head or neck injury.
  • Recurrent or multiple dissections have been demonstrated in select cases.
  • Minor head trauma has also been associated with acute ischemic stroke.
  • The objective of this study was to survey pediatric stroke experts about participation of patients following acute ischemic stroke in high impact, medium impact, and low impact exercise.
  • International Pediatric Stroke Study members were surveyed about athletic participation after stroke.
  • Participants were asked about 2 scenarios: acute ischemic stroke with dissection, and acute ischemic stroke with a negative coagulation work-up and a negative angiogram.
  • Many experts would not allow high impact sports after a dissection, but disagree about recommendations after idiopathic acute ischemic stroke.
  • [MeSH-minor] Acute Disease. Adolescent. Age Factors. Brain / blood supply. Brain / pathology. Brain / physiopathology. Football / injuries. Humans. Male. Prognosis. Risk Assessment. Risk Factors. Secondary Prevention. Soccer / injuries. Vertebral Artery Dissection / complications. Vertebral Artery Dissection / physiopathology. Vertebral Artery Dissection / prevention & control


85. Zhou Y, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Wang X, Wang D, Liu S, Lu J, Zheng J, Zhong N, Ran P: COPD in Chinese nonsmokers. Eur Respir J; 2009 Mar;33(3):509-18
MedlinePlus Health Information. consumer health - COPD.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Being male, of advanced age, lower body mass index (BMI) and lower educational level, having exposure to environmental tobacco smoke, coal and/or biomass smoke, poor ventilation in the kitchen, a family history of respiratory disease and recurrent childhood cough were all independently associated with a higher risk of having COPD among nonsmokers.
  • Nonsmokers with COPD were less likely to present with chronic productive coughs and lower BMI, while more likely to have received a physician diagnosis of asthma and respiratory diseases in childhood, than smokers with COPD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251797.001).
  • [ISSN] 1399-3003
  • [Journal-full-title] The European respiratory journal
  • [ISO-abbreviation] Eur. Respir. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  •  go-up   go-down


86. Karadag B, Karakoc F, Ersu R, Dagli E: Is childhood asthma still underdiagnosed and undertreated in Istanbul? Pediatr Int; 2007 Aug;49(4):508-12
MedlinePlus Health Information. consumer health - Asthma in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is childhood asthma still underdiagnosed and undertreated in Istanbul?
  • BACKGROUND: Childhood asthma is reported to be underdiagnosed and undertreated worldwide.
  • Of these children 45.5% had recurrent asthma attacks (average 4.8 attacks per year) and 24.7% had only the symptom of vigorous fits of coughing.
  • CONCLUSIONS: Underdiagnosis and undertreatment of childhood asthma still seem to be a major problem in the management of childhood asthma, especially in preschool children, even after the recommendations of guidelines.

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17587277.001).
  • [ISSN] 1328-8067
  • [Journal-full-title] Pediatrics international : official journal of the Japan Pediatric Society
  • [ISO-abbreviation] Pediatr Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


87. Pace F, Zuin G, Di Giacomo S, Molteni P, Casini V, Fontana M, Porro GB: Family history of irritable bowel syndrome is the major determinant of persistent abdominal complaints in young adults with a history of pediatric recurrent abdominal pain. World J Gastroenterol; 2006 Jun 28;12(24):3874-7
MedlinePlus Health Information. consumer health - Abdominal Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of irritable bowel syndrome is the major determinant of persistent abdominal complaints in young adults with a history of pediatric recurrent abdominal pain.
  • AIM: To assess the late outcome of teen-agers with a previous history of recurrent abdominal pain (RAP) or irritable bowel syndrome (IBS).
  • CONCLUSION: The study confirms previous observations indicating that pediatric RAP can predict later development of IBS.

  • Genetic Alliance. consumer health - Irritable Bowel Syndrome.
  • Genetic Alliance. consumer health - Young syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):451-6 [10685749.001]
  • [Cites] Arch Dis Child. 1958 Apr;33(168):165-70 [13534750.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):799-804 [11606493.001]
  • [Cites] Pediatrics. 1972 Sep;50(3):429-36 [5056416.001]
  • [Cites] Br Med J. 1973 Jul 7;3(5870):7-9 [4717440.001]
  • [Cites] Arch Dis Child. 1975 Feb;50(2):110-4 [1130815.001]
  • [Cites] Am J Dis Child. 1979 May;133(5):486-9 [433872.001]
  • [Cites] Dig Dis Sci. 1982 Mar;27(3):202-8 [7075418.001]
  • [Cites] N Engl J Med. 1984 Mar 29;310(13):824-9 [6700671.001]
  • [Cites] J Child Psychol Psychiatry. 1986 Mar;27(2):251-60 [3958079.001]
  • [Cites] Pediatrics. 1987 May;79(5):677-82 [3575021.001]
  • [Cites] Dig Dis Sci. 1989 Sep;34(9):1379-86 [2766905.001]
  • [Cites] Headache. 1992 Jul;32(7):353-5 [1526767.001]
  • [Cites] Acta Paediatr. 1993 May;82(5):484-7 [8518527.001]
  • [Cites] Acta Paediatr. 1994 Apr;83(4):433-7 [8025405.001]
  • [Cites] Psychosom Med. 1994 Nov-Dec;56(6):541-50 [7871110.001]
  • [Cites] J Pediatr Psychol. 1995 Apr;20(2):233-45 [7760222.001]
  • [Cites] J Pediatr. 1996 Aug;129(2):220-6 [8765619.001]
  • [Cites] J Child Psychol Psychiatry. 1996 Jul;37(5):519-28 [8807432.001]
  • [Cites] Pediatr Rev. 1997 Sep;18(9):310-20; quiz 321 [9286150.001]
  • [Cites] BMJ. 1998 Apr 18;316(7139):1196-200 [9552994.001]
  • [Cites] J Pediatr. 1998 Jun;132(6):1010-5 [9627595.001]
  • [Cites] Gut. 1999 Sep;45 Suppl 2:II60-8 [10457047.001]
  • [Cites] Pediatrics. 2001 Jul;108(1):E1 [11433080.001]
  • (PMID = 16804973.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087936
  •  go-up   go-down


88. Robins PM, Smith SM, Glutting JJ, Bishop CT: A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain. J Pediatr Psychol; 2005 Jul-Aug;30(5):397-408
MedlinePlus Health Information. consumer health - Abdominal Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized controlled trial of a cognitive-behavioral family intervention for pediatric recurrent abdominal pain.
  • OBJECTIVE: To investigate whether the combination of standard medical care (SMC) and short-term cognitive-behavioral family treatment (CBT) in the treatment of recurrent abdominal pain (RAP) was more effective than SMC alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Pediatr Psychol. 2005 Jul-Aug;30(5):449-52 [15944173.001]
  • (PMID = 15944167.001).
  • [ISSN] 0146-8693
  • [Journal-full-title] Journal of pediatric psychology
  • [ISO-abbreviation] J Pediatr Psychol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Farmer K, Dunn D, Scott E: Psychological factors in childhood headaches. Semin Pediatr Neurol; 2010 Jun;17(2):93-9
MedlinePlus Health Information. consumer health - Headache.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychological factors in childhood headaches.
  • Recurrent headaches in children are most often migraines and are based in a genetic predisposition with a low headache threshold.
  • Childhood headaches are especially complicated for 3 reasons:.
  • This article addresses the mystery surrounding childhood headaches by delving into the influence of school, friends, and family; the impact of divorce; the coping skills required for a child to manage a migrainous nervous system; the potential secondary gain from headaches; psychiatric comorbidities and how to treat them; and the role of psychological intervention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20541100.001).
  • [ISSN] 1558-0776
  • [Journal-full-title] Seminars in pediatric neurology
  • [ISO-abbreviation] Semin Pediatr Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Wohlfahrt-Veje C, Boisen KA, Boas M, Damgaard IN, Kai CM, Schmidt IM, Chellakooty M, Suomi AM, Toppari J, Skakkebaek NE, Main KM: Acquired cryptorchidism is frequent in infancy and childhood. Int J Androl; 2009 Aug;32(4):423-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired cryptorchidism is frequent in infancy and childhood.
  • Our aim was to determine the prevalence of testicular ascent in childhood.
  • A congenital cryptorchid testis with spontaneous postnatal descent followed by recurrence of cryptorchidism was named recurrent cryptorchidism.
  • When including recurrent cryptorchidism the prevalence was 0.2%, 1.2% and 0.8% respectively.
  • Ascensus testis accounts for more than half of cryptorchid testes seen in childhood and occurs in both previously scrotal and cryptorchid testes.
  • We therefore recommend that all boys should have testis position checked regularly during childhood, at least up to 3 years of age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19515170.001).
  • [ISSN] 1365-2605
  • [Journal-full-title] International journal of andrology
  • [ISO-abbreviation] Int. J. Androl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


91. Helgeland H, Sandvik L, Mathiesen KS, Kristensen H: Childhood predictors of recurrent abdominal pain in adolescence: A 13-year population-based prospective study. J Psychosom Res; 2010 Apr;68(4):359-67
MedlinePlus Health Information. consumer health - Abdominal Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood predictors of recurrent abdominal pain in adolescence: A 13-year population-based prospective study.
  • OBJECTIVE: To investigate maternal and child emotional symptoms, physical health problems, and negative life events measured at children's age 18 months and 12 years as potential predictors for self-reported recurrent abdominal pain (RAP) in adolescents (14 years).
  • CONCLUSIONS: This is the first cohort study that finds maternal psychological distress in early childhood to predict RAP in their offspring 13 years later.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20307703.001).
  • [ISSN] 1879-1360
  • [Journal-full-title] Journal of psychosomatic research
  • [ISO-abbreviation] J Psychosom Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


92. Braun PA, Beaty BL, DiGuiseppi C, Steiner JF: Recurrent early childhood injuries among disadvantaged children in primary care settings. Inj Prev; 2005 Aug;11(4):251-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent early childhood injuries among disadvantaged children in primary care settings.
  • OBJECTIVE: To examine differences in social risk factors and health care use between young children with and without recurrent injuries.
  • CONCLUSIONS: Children with recurrent injury were more likely to have social risk factors, and used DHMC more frequently, than children with one or no injuries.
  • Children with risk factors for recurrent injury can be identified and injury prevention counseling can be delivered to their families at their multiple visits to the system.

  • MedlinePlus Health Information. consumer health - Wounds and Injuries.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Future Child. 2000 Spring-Summer;10(1):53-82 [10911688.001]
  • [Cites] Pediatrics. 1999 Jun;103(6 Pt 1):1183-8 [10353926.001]
  • [Cites] Pediatrics. 2002 Apr;109(4):559-65 [11927696.001]
  • [Cites] Pediatr Emerg Care. 2004 Jun;20(6):361-6 [15179143.001]
  • [Cites] MMWR Surveill Summ. 2004 Sep 3;53(7):1-57 [15343143.001]
  • [Cites] Aust Paediatr J. 1980 Dec;16(4):244-7 [7236129.001]
  • [Cites] Am J Dis Child. 1986 May;140(5):487-92 [3962946.001]
  • [Cites] Am J Dis Child. 1988 Jun;142(6):605-11 [3369398.001]
  • [Cites] Pediatrics. 1988 Nov;82(5):707-12 [3186349.001]
  • [Cites] Am J Dis Child. 1989 Mar;143(3):338-42 [2916511.001]
  • [Cites] Am J Dis Child. 1989 May;143(5):556-9 [2718989.001]
  • [Cites] J Pediatr Psychol. 1994 Feb;19(1):79-89 [8151497.001]
  • [Cites] Am J Public Health. 1994 Apr;84(4):587-92 [8154561.001]
  • [Cites] J Public Health Med. 1995 Mar;17(1):39-45 [7786566.001]
  • [Cites] Acad Emerg Med. 1997 Aug;4(8):772-5 [9262693.001]
  • [Cites] Can J Psychiatry. 1997 Aug;42(6):602-10 [9288422.001]
  • [Cites] J Ambul Care Manage. 1997 Jul;20(3):1-18 [10181610.001]
  • [Cites] J Urban Health. 2001 Mar;78(1):141-51 [11368193.001]
  • (PMID = 16081757.001).
  • [ISSN] 1353-8047
  • [Journal-full-title] Injury prevention : journal of the International Society for Child and Adolescent Injury Prevention
  • [ISO-abbreviation] Inj. Prev.
  • [Language] ENG
  • [Grant] United States / ODCDC CDC HHS / CC / R49/CCR 811509
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1730252
  •  go-up   go-down


93. Oskoui M, Webster RI, Zhang X, Shevell MI: Factors predictive of outcome in childhood epilepsy. J Child Neurol; 2005 Nov;20(11):898-904
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predictive of outcome in childhood epilepsy.
  • To identify early predictive factors of outcome in childhood epilepsy, the case records of all children with new-onset epilepsy presenting to a single neurology practice over a 10-year interval were reviewed.
  • At final assessment, 52.6% were in remission, 12.8% had a poor outcome (recurrent seizures on therapeutic antiepileptic drug levels within 6 months prior to the final assessment), and 6.9% were intractable (more than one seizure/month over 1 year with failure of three or more anticonvulsants).

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417860.001).
  • [ISSN] 0883-0738
  • [Journal-full-title] Journal of child neurology
  • [ISO-abbreviation] J. Child Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


94. Moskvina V, Farmer A, Swainson V, O'Leary J, Gunasinghe C, Owen M, Craddock N, McGuffin P, Korszun A: Interrelationship of childhood trauma, neuroticism, and depressive phenotype. Depress Anxiety; 2007;24(3):163-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interrelationship of childhood trauma, neuroticism, and depressive phenotype.
  • Both childhood trauma (CT) and genetic factors contribute to the pathophysiology of depression.
  • We studied the relationship of CT to age of onset (AO) of depression, personality traits, and expression of symptom dimensions in 324 adults with recurrent unipolar depression.

  • MedlinePlus Health Information. consumer health - Child Abuse.
  • MedlinePlus Health Information. consumer health - Post-Traumatic Stress Disorder.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16900462.001).
  • [ISSN] 1091-4269
  • [Journal-full-title] Depression and anxiety
  • [ISO-abbreviation] Depress Anxiety
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


95. Balemans WA, Rovers MM, Schilder AG, Sanders EA, Kimpen JL, Zielhuis GA, Ent CK: Recurrent childhood upper respiratory tract infections do not reduce the risk of adult atopic disease. Clin Exp Allergy; 2006 Feb;36(2):198-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent childhood upper respiratory tract infections do not reduce the risk of adult atopic disease.
  • Longitudinal studies investigating these associations beyond childhood are, however, scarce.
  • OBJECTIVE: To investigate the association between childhood recurrent upper respiratory tract infections (URTI) and asthma, allergic rhinitis (AR) and eczema in adulthood.
  • Children who experienced recurrent URTI before the age of 2 years, between the ages of 2-4 years and between ages of 4 and 8 years were not less likely to have asthma at 21 years of age than children who did not experience recurrent URTI, relative risk (RR) 0.97 (95% confidence interval (CI) 0.65-1.46), RR 1.45 (CI 0.95-2.21) and RR 1.51 (CI 0.97-2.36), respectively.
  • Neither were recurrent URTI associated with a decreased risk of AR, nor eczema at the age of 21 years.
  • CONCLUSIONS: Recurrent URTI in childhood did not reduce the risk of atopic disease in young adulthood.

  • MedlinePlus Health Information. consumer health - Allergy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433857.001).
  • [ISSN] 0954-7894
  • [Journal-full-title] Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • [ISO-abbreviation] Clin. Exp. Allergy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Nevsímalová S, Havlová M, Tauberová A, Prihodová I: [Alternating hemiplegia of childhood (AHC)]. Cas Lek Cesk; 2005;144(10):692-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Alternating hemiplegia of childhood (AHC)].
  • BACKGROUND: Alternating hemiplegia of childhood (AHC) is a rare neurological disease of unknown aetiology characterized by recurrent paroxysmal attacks of side-alternating hemiplegias of variable duration associated with other paroxysmal dysfunctions.

  • Genetic Alliance. consumer health - Hemiplegia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16279436.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


97. Dalla Pozza R, Hartl D, Bechtold S, Urschel S, Kozlik-Feldmann R, Pankuweit S, Belohradsky B, Netz H: Recurrent pericarditis in children: elevated cardiac autoantibodies. Clin Res Cardiol; 2007 Mar;96(3):168-75
MedlinePlus Health Information. consumer health - Pericardial Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent pericarditis in children: elevated cardiac autoantibodies.
  • Recurrent pericarditis is a rare disease in childhood.
  • We report on four patients with recurrent pericarditis in whom antimyolemmal antibodies (AMLAs) were detected.
  • A prolonged persistence of IgM-type AMLAs was found in three patients: two of them presented with acute inflammation as the initial event and one with 48 recurrences during 5.5 years.
  • The fourth patient showed a fast conversion from IgM to IgG-type AMLAs after a less acute initial presentation and showed 4 mild recurrences during the 48-month follow-up.
  • CONCLUSION: We were able to detect AMLAs in four children with recurrent pericarditis.
  • This finding may be attributed to an auto-immunological disease following a first, acute event.
  • We propose the detection of AMLAs in all children with unexplained recurrent pericarditis.
  • Pediatric patients with a persistence of IgM-type AMLAs may face frequent recurrences and should be monitored therefore more closely.
  • [MeSH-minor] Acute Disease. Adolescent. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Child. Drug Therapy, Combination. Echocardiography. Female. Glucocorticoids / therapeutic use. Humans. Immunoglobulin G / immunology. Immunoglobulin M / immunology. Male. Prognosis. Secondary Prevention. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Tex Heart Inst J. 2004;31(4):398-403 [15745292.001]
  • [Cites] Postgrad Med J. 1992;68 Suppl 1:S11-6 [1409209.001]
  • [Cites] J Mol Cell Cardiol. 1994 Jul;26(7):907-13 [7966359.001]
  • [Cites] J Am Coll Cardiol. 2003 Aug 20;42(4):759-64 [12932616.001]
  • [Cites] Am Heart J. 1983 Aug;106(2):329-37 [6869214.001]
  • [Cites] Fortschr Med. 1984 May 10;102(18):516-20 [6376300.001]
  • [Cites] Acta Paediatr. 1998 May;87(5):603-4 [9641750.001]
  • [Cites] Circulation. 1993 May;87(5 Suppl):IV49-65 [8485834.001]
  • [Cites] Br Med J. 1968 May 4;2(5600):272-5 [5646538.001]
  • [Cites] Sem Hop. 1975 Oct 9;51(40):2393-2400 [175486.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1998 Sep;27(3):344-7 [9740210.001]
  • [Cites] J Am Coll Cardiol. 1986 Feb;7(2):300-5 [3944348.001]
  • [Cites] Heart Vessels Suppl. 1985;1:209-17 [2956237.001]
  • [Cites] J Am Coll Cardiol. 1995 Nov 1;26(5):1276-9 [7594043.001]
  • [Cites] Eur Heart J. 2002 Oct;23(19):1503-8 [12242070.001]
  • [Cites] Cardiovasc Pathol. 2002 Mar-Apr;11(2):112-22 [11934603.001]
  • [Cites] Eur Heart J. 2004 Apr;25(7):587-610 [15120056.001]
  • (PMID = 17180574.001).
  • [ISSN] 1861-0684
  • [Journal-full-title] Clinical research in cardiology : official journal of the German Cardiac Society
  • [ISO-abbreviation] Clin Res Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Autoantibodies; 0 / Glucocorticoids; 0 / Immunoglobulin G; 0 / Immunoglobulin M
  •  go-up   go-down


98. Baysal BE: A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia. PLoS One; 2007 May 09;2(5):e436
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A recurrent stop-codon mutation in succinate dehydrogenase subunit B gene in normal peripheral blood and childhood T-cell acute leukemia.
  • Here, I describe that succinate dehydrogenase (SDH; mitochondrial complex II) subunit B gene (SDHB) is somatically mutated at a cytidine residue in normal peripheral blood mononuclear cells (PBMCs) and T-cell acute leukemia.
  • Transcript sequence analyses in leukemic cell lines derived from monocyte, NK, T and B cells indicate that the mutational mechanism targeting SDHB is operational in T-cell acute leukemia.
  • Accordingly, substantial levels (more than 3%) of the mutant SDHB transcripts are detected in five of 20 primary childhood T-cell acute lymphoblastic leukemia (T-ALL) bone marrow samples, but in none of 20 B-ALL samples.
  • CONCLUSIONS: The identification of a recurrent, inactivating stop-codon mutation in the SDHB gene in normal blood cells suggests that SDHB is targeted by a cytidine deaminase enzyme.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Oct 15;104(8):2224-34 [15231578.001]
  • [Cites] Hum Genet. 2003 Aug;113(3):228-37 [12811540.001]
  • [Cites] Eur J Haematol. 1999 Sep;63(3):180-91 [10485273.001]
  • [Cites] Mol Cell Biol. 2004 Dec;24(24):10933-40 [15572694.001]
  • [Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]
  • [Cites] BMC Med Genet. 2005;6:39 [16288654.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Jun;7(6):415-25 [16723977.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7615-20 [16885361.001]
  • [Cites] Anal Biochem. 2007 Jan 1;360(1):84-91 [17107651.001]
  • [Cites] J Exp Med. 2007 Jan 22;204(1):7-10 [17190841.001]
  • [Cites] BMC Biol. 2007;5:12 [17376234.001]
  • [Cites] J Appl Physiol (1985). 2005 Feb;98(2):715-21 [15649883.001]
  • [Cites] Science. 2000 Feb 4;287(5454):848-51 [10657297.001]
  • [Cites] Nat Genet. 2000 Aug;25(4):375-6 [10932175.001]
  • [Cites] Am J Hum Genet. 2002 Jan;70(1):38-50 [11727199.001]
  • [Cites] Annu Rev Immunol. 2002;20:165-96 [11861601.001]
  • [Cites] J Med Genet. 2002 Mar;39(3):178-83 [11897817.001]
  • [Cites] Trends Genet. 2003 Apr;19(4):207-16 [12683974.001]
  • [Cites] Annu Rev Genet. 1990;24:305-26 [2088171.001]
  • (PMID = 17487275.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / CA114766; United States / NCI NIH HHS / CA / U24 CA114766; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA11236
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Terminator; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.3.99.1 / Succinate Dehydrogenase
  • [Other-IDs] NLM/ PMC1855983
  • [General-notes] NLM/ Original DateCompleted: 20070727
  •  go-up   go-down


99. Lizcova L, Zemanova Z, Malinova E, Jarosova M, Mejstrikova E, Smisek P, Pospisilova D, Stary J, Michalova K: A novel recurrent chromosomal aberration involving chromosome 7 in childhood myelodysplastic syndrome. Cancer Genet Cytogenet; 2010 Aug;201(1):52-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel recurrent chromosomal aberration involving chromosome 7 in childhood myelodysplastic syndrome.
  • In this report, we present an unusual cytogenetic abnormality leading to loss of both the whole short and whole long arms of chromosome 7, which was found in the bone marrow cells of three pediatric patients with MDS.
  • Together with one previously published case, this chromosomal aberration represents a new rare recurrent karyotypic abnormality involving chromosome 7 in children with MDS.

  • Genetic Alliance. consumer health - Myelodysplastic syndromes.
  • MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633770.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Courtet P: [Suicidal risk in recurrent depression]. Encephale; 2010 Dec;36 Suppl 5:S127-31
Hazardous Substances Data Bank. LITHIUM CARBONATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Suicidal risk in recurrent depression].
  • Recurrent depression represents a major target of suicide prevention, due to its high prevalence and its strong association to Suicidal Behaviour (SB).
  • Thus, suicidal risk in recurrent depression being related to severity, partial response to treatment, chronicity and recurrences, the expectancies of treatment should be elevated.
  • Consequently, the evaluation will be focused on the specific suicidal vulnerability: personal and family history of SB, hopelessness and impulsive aggression, and childhood maltreatment.
  • Indeed, the priority is first to treat adequately recurrent depression, as it is clear that too many patients do not receive such a treatment.

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Suicide.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 L'Encéphale. Published by Elsevier Masson SAS.. All rights reserved.
  • (PMID = 21211632.001).
  • [ISSN] 0013-7006
  • [Journal-full-title] L'Encéphale
  • [ISO-abbreviation] Encephale
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antidepressive Agents; 2BMD2GNA4V / Lithium Carbonate
  •  go-up   go-down






Advertisement